Index

Notes: Entries in *italics* refer to figures whilst those in **bold** refer to tables/boxed material.

A

abdominal bloating, pregnancy and 256, 258
abdominal ectopic pregnancy 125
abdominal examination 18, *18*
abdominal pain
  ectopic pregnancy 119
  ovarian torsion 478
  placental abruption 196
  preterm labor 183
abdominal surgery 364–365
  see also laparotomy
abnormal labor *see* dystocia
abortion
  spontaneous (miscarriage) *see* spontaneous abortion
  therapeutic *see* therapeutic abortion
abruptio placentae *see* placental abruption
abscess(es)
  Bartholin gland *447*, 447–448
  breast 343
  tubo-ovarian 313
  vulval 449
abstinence, contraception and 276
acanthosis nigricans, vulval lesions 448
accelerations (fetal heart rate) 91, 92, *93*
accessory breast tissue 344
ACE inhibitors, contraindication in pregnancy 207–208
achrochordons (skin tags), vulval 448
acidemia, definition 91
acidosis
  definition 91
  fetal scalp pH 97
acquired immunodeficiency syndrome *see* HIV infection/AIDS
active phase (labor) 104, **104,** *104*
activin, follicular phase and 34
acupuncture, dysmenorrhea treatment 401
adenocarcinoma
  Bartholin gland 447–448
  fallopian tube 483
adenoma, breast 347
adenomyosis 321–322
adenosis, breast 346
adnexal, definition 477
adnexal masses 477–484
  evaluation 477–478
    postmenopausal women 477–478, 479
    premenopausal women 477, **478**
  fallopian tubes 483
  ovarian *see* ovary(ies), masses
  tubo-ovarian abscess 313
  see also specific types
adolescence
  breast tissue 344, *345*
  contraception 5–6
  life-long patient care 4–5
  pregnancy 5, 81
  puberty *see* puberty
  sexuality 492
adoption 411
adrenal gland
  fetal 78, *78*
  polycystic ovary syndrome and *388*, 388–389
  tumors, virilization and 395
  see also specific hormones
adrenarche 4
adverse outcomes 528
  definition 528
  disclosure and discussing unintended outcomes 513, 529
  documentation and prevention 531
  informed consent and 529
  risk management 530
  three delays model 528, *528*
  see also specific outcomes
agenesis, definition 25
AIDS *see* HIV infection/AIDS
alcohol
  preconception care and pregnancy 82, **82,** *82*
  preterm birth/perinatal mortality and 235
alcohol abuse questionnaire 82, **82**
allergy, preterm labor/birth and 139
allograft rejection, preterm labor/birth 139
α-fetoprotein (AFP) 65, 66, 69
  multifetal pregnancy 174
ambulatory pH monitoring 259, *259*
amenorrhea 378–386
  anovulatory cycles 404
  breast-feeding and 343
  definition 31
    primary *vs.* secondary 378, 382
  primary 378, 382–384
    assessment/evaluation 382
    diagnosis/treatment algorithm 382, *383*
    etiology 382, **382**
    Turner syndrome and 382–384
  secondary 378–382
    diagnosis/treatment algorithm 379, *379*
    etiology 378–379, **380**
    hypothalamic dysfunction 379–380
    ovarian dysfunction 381
    pituitary dysfunction 380–381
    pregnancy *see* pregnancy
    uterine dysfunction 382
  see also specific causes
American Cancer Society, cervical cancer screening guidelines 61
American College of Obstetrics and Gynecology (ACOG)
  Code of Ethics 519
    limits of conscientious refusal 523
    maternal autonomy *vs.* fetal beneficence 520
  labor induction guidelines 234
  lawsuit effects on OB/GYN practice 527, **527**
  post-term pregnancy, fetal monitoring 267
  testing recommendations in rhesus isoimmunization 162
American Medical Association (AMA), Code of Ethics 517, 519, **519**
  communicable disease and 524
American Society for Reproductive Medicine (ASRM), polycystic ovary syndrome criteria **387,** 387–388
American Society of Colposcopy and Cervical Pathology (ASCCP), cervical cancer screening guidelines 61, **61**
amitriptyline, chronic pelvic pain management 328
amniocentesis 51, 69
  multifetal pregnancy 173, 174
  PROM diagnosis 197
  rhesus isoimmunization and *163*, 163–164
  spontaneous abortion and 129
amnioinfusion 97
amnionicity
  definition 167
  determination 168, 172, *172*
amniotic fluid 78
  bilirubin in *163*, 163–164
  fern-leaf pattern and PROM diagnosis 196, *196*
  fetal metabolic status and 97
  volume
    assessment in multifetal pregnancy 174
    excess 167
    post-term pregnancy 267
Amsel's criteria, bacterial vaginosis 298–299
androgen(s)
  follicular phase and 34
  polycystic ovary syndrome and *388*, 388–389, 391
  Sertoli–Leydig cell tumors 483
  sexual dysfunction management 492, **493**
  Turner syndrome 384
  see also specific hormones
anemia
  dysfunctional uterine bleeding 384

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

hemolytic disease 161
iron deficiency, postpartum outcomes 237
anesthesia
abnormal labor and 146–147
multiple births 176
therapeutic abortion and 286
aneuploidy
definition 43, 65, 167
disorders 43–47
monosomy 46–47
polyploidy (trisomy) 43–46
spontaneous abortion and 128, *128*
see also specific disorders
fetal growth restriction and 182, *182*
screening tests *see* prenatal testing
Angelman syndrome 50
anger, domestic violence and 496
angiogenesis
cancer and 437–438
luteal phase and 36
anogenital warts 448, 454
anorexia 9
anovulatory cycles
amenorrhea and 404
dysfunctional uterine bleeding 384
etiologies 407
infertility 404, 407
in PCOS 392–393, **393,** 407
antenatal care *see* antepartum care
antepartum care 85–89
definition 81
general recommendations 87, **88**
glucose screening 86
HIV infection and 224, **225,** *225*
initial visit 86
maternal mortality prevention 236
multifetal pregnancies and 173–174
nutritional support/weight management 87
perinatal mortality prevention 236
prenatal screening *see* prenatal testing
repeat visits 86
schedule 85
serological tests 86
ultrasonography 86
vaccinations/prophylaxis 86–87
antibiotics
Clostridium difficile and 236
GBS management 225–226, **226**
maternal mortality prevention 238
pelvic inflammatory disease 312, **312**
preterm labor/birth management 142–143, 188
PROM and 198, **200–201**
puerperal endometritis 215
syphilis management 229
urinary tract infections 336
see also specific drugs
anticonvulsants, teratogenesis and **83,** 85
antidepressant drugs
breast-feeding and 247–248, **248**
postpartum mood disorders 247
pregnancy and 244–245
adverse effects 244, 245, **245**
contraindications/decision not to use 244
discontinuation 244
strategies for use 245
see also specific drugs/drug types
'anti-dumping law' 531
antihypertensive pharmacologic therapy
breast-feeding and 208
pregnancy and **156,** 207–208
ACE inhibitor contraindication 207–208
indications for/goals 206–207
pre-eclampsia–eclampsia syndrome 155–156, **156**
severe postpartum hypertension **208**
see also specific drugs
antiphospholipid syndrome, recurrent pregnancy loss 131
antipsychotic drugs (neuroleptics)
breast-feeding and 248
pregnancy and 246
antiviral drugs
HIV infection/AIDS management 223, 224, **225**
HSV management 223, **223**
transmission reduction in discordant couples **309**
see also specific drugs/infections
anxiety disorders 9
following sexual assault 497
management 246
menopause and 426
pregnancy and 246, **246**
symptoms 246
Apgar score 110, **110**
definition 107
preterm infants 108
aphthous ulcers, vulval 449
apical prolapse 331
ArginMax, sexual dysfunction management 492
aromatase inhibitors
infertility treatment in PCOS 393
pelvic pain management 320
arousal (sexual)
disorders 490
males *vs.* females 488
arrest disorder, definition 145
arterial embolization
uterine atony management 216
uterine leiomyoma management 7, 466, **468**
ascites, definition 15
Asherman syndrome, secondary amenorrhea 382
Asoprisnil, uterine leiomyoma management **468**
asphyxia
definition 91
fetal heart rate and **98**
assault, sexual *see* sexual assault
assisted reproductive technology (ART) 409–410
ethical issues 411
indications 409–410
key steps 409, *409*
male factor infertility 406, **412**
multifetal pregnancies 168, 169, 410
legislation and 170
in PCOS 393
see also specific techniques
asthma
definition 251
pregnancy and
chief complaints/examination 257
diagnosis 252, *252*
epidemiology/prevalence 254
etiology/pathogenesis and 255
laboratory evaluation 259
treatment and 260
atrophic vaginitis 301
atypical breast hyperplasia 346–347, **348**
auscultation
abdominal examination 18, *18*
definition 15
intermittent, fetal surveillance and 96, *96*
autoimmune disorders 6
see also specific disorders
autonomy
definition 518, **518**
maternal
fetal beneficence *vs.* 519–521
nonmaleficence *vs.* 521–522
Auto-Pap Screening System 20
autosomal dominant disorders 49
autosomal recessive disorders 49
autosome, definition 41
avidity index, definition 219

B

'baby blues' 247
back pain
definition 251
pregnancy and
chief complaints/examination 257–258
diagnosis 252, *253*
epidemiology/prevalence 254
etiology/pathogenesis and 255
laboratory evaluation 259
prevention 260, **263**
treatment *260,* 260–261
bacterial infections
antibiotic therapy *see* antibiotics
pregnancy and 225–229, 298
GBS 225–229
maternal mortality and 238
premature labor and 142–143, 186, 198, 236
sexually-transmitted
non-ulcerative lesions 305–306
ulcerative lesions 306–307, **308,** 308–309
see also specific infections/organisms

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

bacterial vaginosis (BV) **293,** 294, 298–300
clinical features/diagnosis 298–299
diagnostic criteria 298–299
laboratory evaluation 299, *299*
Pap test and 299
vaginal discharge 298, *298*
epidemiology 298
etiology/pathogenesis 298
pregnancy and 298
maternal mortality 238
premature labor and 186
treatment options 299–300
treatment 299–300
abortion/hysterectomy and 299
drugs used 299, **299**
symptomatic 299
balanced translocations 48
barrier contraceptive methods 277
Bartholin glands *447,* 447–448
Behçet disease, vulval lesions 449
beneficence
definition 518, **518**
fetal, maternal autonomy *vs.* 519–521
benzodiazepines 246
neonatal effects of exposure 246, **246**
PMS/PMDD management 418
beta-mimetic agents, as tocolytics **186,** 187
Bethesda cervical cancer classification system
2001 revision 58, **58**
Bethesda System, cervical cancer classification 57–58
bilirubin
amniotic fluid levels *163,* 163–164
excessive *see* hyperbilirubinemia
bimanual examination *19*
biometry, fetal growth restriction 185
biophysical profile (BPP)
fetal growth restriction 185
multifetal pregnancy and 174
post-term pregnancy 267
PROM management and 197–198
biopsies 20–21
breast mass evaluation 345, 354
cervix 20–21
endometrial *see* endometrial biopsy
lymph nodes in breast cancer *355,* 355–356
vagina 21
vulva 21, 450
see also specific types/methods
bipolar disorder
breast-feeding and medications 248
pregnancy and 245
BIRADS (Breast Imaging Report and Data System) 353–354, *354*
birth *see* labor/delivery
birth control *see* family planning
bisphosphonates, menopause 428
bladder pain syndrome 326
bleeding
dysfunctional uterine *see* uterine bleeding, dysfunctional
sentinel bleeding 214
therapeutic abortion and 289
third trimester *see* third trimester bleeding
see also hemorrhage; *specific types/causes*
blighted ovum, definition 127
blood glucose monitoring, pregnancy 261
blood volume, multifetal pregnancies 170
body language, patient–provider communication 508, 509
body mass index (BMI)
polycystic ovary syndrome and 393
infertility 392
insulin resistance 389, *389*
secondary amenorrhea and 379, 380
body temperature, ovulation and 404
'boggy' uterus, adenomyosis and 321
bone density
breast cancer survivors and 357
menopause and 428
bony pelvis
anatomy 29–30, 100, *100*
labor mechanics and 100–101
measurement *100,* 100–101
obstructed delivery and 237
see also entries beginning pelvic
borderline tumors 478
bowel hypersensitivity, dysmenorrhea 398
bradycardia, fetal 92
BRCA1/2 mutations 352, 437
breast cancer 352, 353
cancer prevention in carriers 352–353, **358,** 373, **438,** 481
ovarian cancer 437, **438,** 479, 481
breast(s) 341–350
accessory breast tissue 344
benign disease 345–348
abscess 343
adenoma 347
cancer risk and 345, 346, 347, **348**
carcinoma in situ 347
classification 345
fat necrosis 347, *348*
galactocele 343
lipoma 347
mastitis and inflammatory masses 343, 346, 347
nonproliferative 345–346
proliferative with atypia 345, 346–347, **348**
proliferative without atypia 345, 346
see also specific lesions
cancer *see* breast cancer
density
age effects 345
HRT and 11, *11*
development 344, *345,* 382
Turner syndrome and 383–384
examination 341–342, 353
lactation 341, 342
disorders associated 343
see also breast-feeding
masses 345
benign *see above*
biopsy 345, 354
imaging 345, 354, *354*
malignant *see* breast cancer
nipple discharge *343,* 344
pain (mastalgia) 344
structure 341, *341*
see also mammography
breast cancer 351–360
diagnosis 354–355
epidemiology 351
etiology/pathophysiology 10, 351–352
cancer stem cells 438
genetic factors 352, 353
HRT and 10–11, 352, 429
oral contraceptives 352
pregnancy and 351, 357
reproductive hormones and 351–352, **357–358**
reproductive risk factors 351
lymph node involvement **355,** *355,* 355–356
nipple discharge and 344
postmenopausal women 10–11, 351
prevention 352–353
bilateral mastectomy 353
exercise 351
hormonal 352–353, **358**
life-style modification 351
quantitative risk assessment tools 352
screening 353–354
breast examination 353
mammography 353–354, *354*
MRI 354, *354*
surgical staging 355
survival rates **355**
survivors, medical care 356–357
bone density and osteoporosis 357
fertility issues 356–357
HRT 357
treatment 355–356
adjunctive therapy 356
bone density and 357
factors affecting 355, **355**
fertility and 356–357
initial surgical treatment 355–356
locally advanced cancer 356
local therapy 355–356
radiotherapy 356
see also mammography
Breast Cancer Risk Assessment (BRCA) tool 352
breast cysts 345–346
breast-feeding 342
amenorrhea and 343
antidepressants and 247–248, **248**
antihypertensives and 208
antipsychotics/mood stabilizers 248
breast cancer reduction and 351
breast disorders associated 343

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

contraception and 343–344
health benefits 342
HIV and 224, 342
maternal nutrition 9–10
neonatal care 112, **114**
sexuality/sexual dysfunction and 492
Breast Imaging Report and Data System (BIRADS) 353–354, *354*
breast milk 341, 342
see also breast-feeding
Burch procedure 335, *335*

C

CA-125, ovarian cancer diagnosis 477–478, 479
calcium channel blockers, as tocolytic agents 188
calcium supplements, PMS/PMDD management 418
canalization, definition 25
cancer 435–440
angiogenesis and 437–438
cellular characteristics/behavior 435, *435*
epigenetics and 438
hormonal contraception and 279
immunology 438
multistep carcinogenesis 437
oncogenes 437
stem cells 438
see also tumor(s); *specific malignancies*
Candida albicans 296
candidiasis
vaginal overgrowth 296
vulvovaginal *see* vulvovaginal candidiasis
cannabis, preterm birth/perinatal mortality and 235
carbohydrate metabolism, pregnancy-related changes 75, **78–79,** 86
carcinoma in situ, breast 347
cardiac output, multifetal pregnancies and 170
cardiotachometer 92
cardiovascular system
fetal circulation 77–78
see also fetal heart rate (FHR)
hormonal contraceptives and 279
maternal changes during pregnancy *75,* 75–76
multifetal pregnancies and 170
menopause and 11, 429
neonatal transition 108, *109*
Carnett's test 327
carriers, genetic disorders 49
cell nucleus, definition 41
cephalopelvic disproportion (CPD), dystocia and 147
certification 528
cervical cancer 457–459
classification/terminology **57,** 57–58, **58,** 453
detection rates and 61, **61**
colposcopy 20–21
epidemiology 57, 459
etiology/pathogenesis
hormonal contraception and 279
HPV and *see* human papilloma virus (HPV)
FIGO staging **454,** 457, *458,* **459**
global burden 459
histological appearance *60*
premalignant lesion *see* cervical neoplasia
prevention
screening *see* cervical screening
vaccination 4–5, 455, **459–460**
survival **459**
treatment 62, 457–458
cervical dilatation, therapeutic abortion and 286
cervical fluid, PROM diagnosis 196
cervical insufficiency
definition 135
preterm labor/birth 139
spontaneous abortion 131
cervical laceration, therapeutic abortion and 289
cervical length (CL), preterm labor and 141, 142, **142,** 145, 185
PROM and 192, *192*
cervical neoplasia 453–457
classification/nomenclature 453, *453,* **454**
diagnosis 456
HPV and pathogenesis *see* human papilloma virus (HPV)
as premalignant lesion 453
prevention
screening *see* cervical screening
vaccination 455, **459–460**
regression 457
treatment 457
cervical ripening
definition 135
induction methods *268,* 268–269
therapeutic abortion and 287, *287*
cervical screening 57–64, 455–456
alternative approaches in developing countries 459
cervical–vaginal cytology 455
Pap smear *see* Pap smear
combined test 456, **456**
direct visual inspection 456
effectiveness 57
guidelines 61, **61**
HPV DNA testing 61–62, 455–456
cervicography, cervical screening and 456
cervicoscopy, cervical screening and 456
cervicovaginal secretions, definition 135
cervix 28
biopsy 20–21
displacement in endometriosis 316, *316,* 399, *399*
ectopic pregnancy 125
incompetence *see* cervical insufficiency
injury
abortion and 289
infertility and 408
long-term outcomes 457
lesions 453–460
cancer *see* cervical cancer
diagnosis 456
neoplasia *see* cervical neoplasia
preservation during hysterectomy 367, **375**
speculum examination 19
vaginitis diagnosis 295
punctate hemorrhages 300
see also entries beginning cervico-/cervical
cesarean delivery
multiple births 177
obstructed births 237
third trimester bleeding and 199
chancroid 308, **308**
chemical contraceptive methods 277
chemical pregnancy, definition 127
chemoradiotherapy, cervical cancer therapy 457–458
chemotherapy
breast cancer 356
endometrial cancer 474, **475**
malignant molar pregnancies 444
ovarian cancer 480
primary ovarian failure 423
children
breast tissue 344
domestic violence 496
Chlamydial cervicitis 306, *306*
hormonal contraception and 279
Chlamydial infections 306, *306,* 308
infertility and 406
prophylactic treatment following sexual assault 497
see also specific conditions
Chlamydia trachomatis 306, *308*
cholecystitis
definition 251
pregnancy and
chief complaints/examination 258
diagnosis 252–253, *253*
epidemiology/prevalence 254
etiology/pathogenesis and 255
laboratory evaluation 259
treatment 261
cholestasis
definition 251
pregnancy and
chief complaints/examination 258
diagnosis 252
epidemiology/prevalence 254
etiology/pathogenesis and 255
laboratory evaluation 259
treatment 261
chorioamnionitis, maternal mortality and 238
choriocarcinoma 443
chorionicity *172*

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

definition 167
determination 168, *168,* 171–172, *173*
fetal gender and 172
intertwin membrane 172–173
membrane origin 173
number of placental masses and 172
chorionic villus sampling (CVS) 51, 68
multifetal pregnancy 173, 174
spontaneous abortion and 129
chromosome(s) 42–43
abnormalities *see* chromosome abnormalities
definition 41
X-chromosome disorders *see* X-chromosome disorders
chromosome abnormalities 43–50
fetal growth restriction and 182, *182*
numerical 43–47, 128, *128*
see also aneuploidy
prenatal detection *see* prenatal testing
spontaneous abortion and 128
structural 47–49
see also specific abnormalities/disorders
chromosome deletions 47
chromosome duplications 47
chromosome translocation(s) 43, *48*
definition 42
mechanisms 47–48
see also specific types
chronic hypertension, in pregnancy *see under* hypertension, in pregnancy
chronic illness
management, medical economics and 503
sexuality/sexual dysfunction and 492
chronic pelvic pain *see* pelvic pain
climacteric *see* perimenopause
clinical ethics *see* ethical issues
cliterodynia 490
clomiphene, anovulatory infertility treatment in PCOS 392, **395**
Clostridium difficile, clindamycin use and 236
cocaine, uterine rupture risk 194
cognition, menopause and 426
cognitive behavioral therapy (CBT), female sexual dysfunction and 491
cold stress, neonates 108–109
colposcope *20*
colposcopy *20,* 20–21, 456
sexual assault 497
combination pill 278, **278**
dysmenorrhea treatment 401, **402**
hirsutism management 394
menopausal hot flushes and 427
pelvic pain and endometriosis management 318–319
PMS/PMDD management 418
polycystic ovary syndrome and 392
communication 507–516
core values (physician) 507, **507**
patient–provider 508–513
body language and 508, 509
cross-cultural interactions 513–514
delivering information to patient 510–511, **510–511**
difficult patients 515
disclosing medical errors 513
eliciting information at interview 508–510
see also history taking
empathy 512
giving bad/difficult news 511–513, **512**
importance of 508
interpreters and 514, **514**
litigation prevention and 528, 530
patient literacy and 511
patients with limited language skills 514
research subjects and 515
terminating relationship 515
physician–physician 515–516
complement system, preterm labor/birth 139
completed abortion, definition 127
conceptus, definition 41
condoms 277
condylomas 309, 448, 454
see also specific types/causes
condylomata acuminata 448
diagnosis 456
congenital abnormalities
chromosomal etiology *see* chromosome abnormalities
fetal growth restriction and 182, 185
spontaneous abortion and 129
congenital cytomegalovirus (CMV) 220, **221, 231**
congenital syphilis 228, **228,** 307
congenital toxoplasmosis 230–231
clinical manifestations **231**
management 230
prevention 230, **230**
conization 457
conjugated equine estrogen (Premarin) **430**
consent, informed 510–511, **510–511,** 529
constipation, pregnancy and 256, 258, 262
contingent sequential testing 68
continuous electronic fetal heart rate monitoring 96–97
contraception 5–6, 275–284
breast-feeding and 343–344
compliance 275
emergency 281–282, 497
ethical dilemmas 523–524
following sexual assault 497
medical factors 275–276
contraindications 275, **276,** 279
methods 276–280
barrier 277
behavioral 276
hormonal *see* hormonal contraceptive methods
IUDs *see* intrauterine device (IUD)
see also specific methods
patient issues 275–276
social/cultural factors 275
WHO guidelines 5, **6**
contraceptive sponge 277
contractility, definition 135
contractions (uterine) *see* uterine contractions
contraction stress test (CST), post-term pregnancy 267, *267*
convulsions
anticonvulsants and teratogenesis **83,** 85
eclamptic 149, 150, 155
cordiocentesis, rhesus isoimmunization diagnosis 163, *163*
cornual (interstitial) pregnancy 124, **125**
corpus luteum 36, *36,* 37
corticosteroids, lung maturation *see* steroid-induced lung maturation
corticotropin-releasing hormone (CRH), preterm labor/birth and 139–140, **148**
credentialing 528
Crohn disease, vulval lesions 449
cultural factors
contraception and 275
patient–provider communication 513–514
curettes 21, *21*
cyst(s)
Bartholin gland *447,* 447–448
breast 345–346
fallopian tubes 483
mesosalpingeal cysts 483
ovary *see* ovarian cysts
vaginal wall 448
cystocele (anterior prolapse) 331, *332*
cystoscopy, urinary incontinence diagnosis 334
cytomegalovirus (CMV)
clinical features associated 220, *220*
infection rates/epidemiology 220
pregnancy and 220–222
diagnosis of maternal/fetal infection 220, *221*
neonatal sequelae 220, **221, 231**
prevention 220, 222
screening 222
cytoplasm, definition 41

D

danazol, pelvic pain management 320
decelerations (fetal heart rate) *see* fetal heart rate (FHR), decelerations
depression 8–9
diagnostic criteria 243, **243**
epidemiology 243
following sexual assault 497
menopause and 426

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

postpartum *see* postpartum depression
during pregnancy *see* depression, pregnancy and
depression, pregnancy and 9, 243–245
impact on fetus 242, 244, **244**
impact on neonate/infant 244, **249**
incidence 243
risk factors 243, **243**
treatment options 243–245
decision not to medicate 244
medication *see* antidepressant drugs
non-pharmacological 246, 248
dermatosis, vulvar 302
descent (fetal) 101, *103*
desire disorders 489–490
diabetes mellitus
definitions 251
pregnancy and
chief complaints/examination 258
diagnosis 253
epidemiology/prevalence 254
etiology/pathogenesis and 255
gestational diabetes *see* gestational diabetes
management 261
preconception care and 84–85
preterm birth/perinatal mortality and 236
spontaneous abortion and 129
type 1 251, 255
type 2 251, 254, 255
diaphragm, contraceptive 277
dietary interventions
dysmenorrhea treatment 400
infertility and 409
premenstrual syndrome treatment 418
see also nutrition
dilation (dilatation) and curettage (D&C) 21, 374
complications/risks 374
ectopic pregnancy and 121–122, *122*
molar pregnancy, hydatidiform mole 442, 443
as office procedure 374
spontaneous abortion management 130
therapeutic abortion 286
dilation (dilatation) and evacuation (D&E) 287
dilation (dilatation) and extraction (D&X) 288
dimeric inhibin A 65
dizygotic siblings
definition 167
twin birth rate 168
DNA (deoxyribonucleic acid) 42
definition 41
fetal in maternal blood 52
methylation, cancer and 438
microarray chips, prenatal testing 53, *54*
repair genes, cancer and 436, 437, 472
see also chromosome(s); genetics/genomics
domestic violence *495,* 495–496
dominant traits/disorders 49
donovanosis 308–309
Doppler ultrasonography 23
fetal growth restriction
assessment 185–186, *186*
management options and 188–189
fetal surveillance 96
rhesus isoimmunization
diagnosis 159, *160,* **164–165**
Down syndrome *see* trisomy 21 (Down syndrome)
drospirenone, PMS/PMDD treatment **419**
drug(s)
illegal/abuse
pregnancy and, maternal autonomy *vs.* fetal beneficence 520
preterm birth/perinatal mortality and 235
uterine rupture risk 194
medical economics and 502
preconception care and pregnancy 82, **83**
spontaneous abortion and 129
see also specific drugs/drug types
ductal epithelial hyperplasia 346
ductus arteriosus, closure 108
due date calculation 265, *265*
duty of care 530
dyschezia, endometriosis 316
dysgerminomas 481–482
dyslipidemia, polycystic ovary syndrome and 391
dysmenorrhea 397–402
definitions 397
diagnosis/assessment 397
history/chief complaint 398–399
laboratory evaluations 399
physical assessment 399, *399*
severity scoring 398, **398**
endometriosis 316, 399
epidemiology/prevalence 397
etiology/pathophysiology 398
onset 397, **397**
primary 397, 399
secondary 397
treatment 399–401
combined contraceptive pill 401, **402**
failure 402
levonorgestrel-releasing intrauterine system 401
nifedipine 401
nonpharmacological 400, 401
NSAIDs 400, **400**
unproven 401
dyspareunia 490
endometriosis 316
dystocia 145–148
definitions 135, **145,** 145–146
diagnosis 146
epidemiology/prevalence 146
etiology/pathophysiology 146–147
cephalopelvic disproportion 147
hypocontractile uterus 146
neuraxial anesthesia 146–147
persistent occiputoposterior position 147
post-term delivery 266, *266,* 269
risk factors 146, **146**
first stage **145,** 146
management 147–148
first stage 147
second stage 147–148
second stage **145,** 146

E

eating disorders 9
eclampsia *see* pre-eclampsia–eclampsia syndrome
ectopic pregnancy 119–126
definition 15, 119
diagnosis 119, 120–122
D & C 121–122, *122*
HCG levels 119, 121, 123
heterotopic pregnancy and 124
physical examination 120
serum progesterone 121
ultrasonography 119, 121, *121*
etiology/pathophysiology 119–120, **120,** 125
history 120–122
maternal mortality 122, 125
prevalence 119
sites 119, *120,* 124
symptoms/signs 119, 120
treatment options 122–125
expectant management 124
heterotopic pregnancy and 124
medical 122–123, *123,* **124**
nontubal pregnancy 124–125, **125**
surgical 122
see also specific methods
Edinburgh Postnatal Depression Scale 247
Edwards syndrome (trisomy 18) 45, *45*
electronic health records
medical economics and 502
preventing harm and 531
embryogenesis, genital *see* genital embryogenesis
embryonal carcinoma 482
emergency contraception 281–282
following sexual assault 497
Emergency Treatment and Active labor Act (EMTALA) (1986) 531–532
empathy, patient–provider communication 512
empty sella syndrome, secondary amenorrhea 381
endocervical curettage 21, *21*
endocrine system
disorders 6
pregnancy related changes 6, 75

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

preterm labor/birth and 139–140, **148,** 236
spontaneous abortion and 129
see also specific disorders
fetal endocrinology 78, *78*
see also specific systems/hormones
endodermal sinus tumor 482
end-of-life, medical economic issues 503
endometrial biopsy 21, *22,* 374–375
cancer detection/diagnosis 472–473, **473**
infertility diagnosis/evaluation 405
polycystic ovary syndrome and 394
endometrial cancer 471–476
definition 471
diagnosis 471, 472–473
biopsy 472–473, **473**
history/chief complaint 472
physical examination 472
epidemiology 471, 472
FIGO staging system 473, **473**
follow-up 474
management
adjuvant treatments 474, **475**
surgical staging/treatment 473–474
ovarian cancer and 474
pathology/pathogenesis 436, 471, *471,* 472
Lynch syndrome and 436, 473
premalignant lesion 471
prevention 472
recurrent disease 474
screening 473
type I endometrioid 471
PTEN and 436, 472
type II 471
p53 link 472
endometrial hyperplasia 471
polycystic ovary syndrome and 394
endometriomas 317–318, 373
endometriosis 6–7, 315–321
definition 15, 315
diagnosis/clinical features 7, 317
dysmenorrhea and 399
history/symptoms 6–7, 316, 317
laboratory evaluations 317
pelvic pain *see* pelvic pain
physical examination 316, *316,* 399, *399*
surgical 317
differential diagnosis 317
epidemiology/prevalence 6, 315, *315*
etiology/pathophysiology 315–316
common locations 317
ovarian cysts and 316, 317–318
infertility and 7, 318, 408
staging 317, *318*
treatment 7, *8,* 317–321, 408
endometriomas 317–318
hormonal 318–321, **319, 320**
infertility management 318, *319*
pelvic pain *see* pelvic pain
surgical 321, **322, 323**
endometritis, therapeutic abortion and 288
endometrium
cancer *see* endometrial cancer
endometriosis *see* endometriosis
menstrual cycle changes 436
therapeutic abortion and infection 288
see also entries beginning endometrio-/endometrial
engagement (fetal) 101, *103*
environmental factors
fetal growth restriction and 182–183
primary ovarian failure 423
spontaneous abortion and 129
see also specific factors
epidural anesthesia
abnormal labor and 146–147
multifetal pregnancy/birth 176
epigastric pain, pre-eclampsia–eclampsia syndrome 152
epigenetics 50
cancer and 438
epilepsy
anticonvulsants and teratogenesis **83,** 85
preconception care and 85
see also convulsions
episiotomy 105, *105*
best evidence **106**
external genitalia anatomy and 28, *28*
epithelial breast hyperplasia 347
Escherichia coli, urinary tract infections 336
estradiol
breast cancer and **357–358**
menopausal symptoms and 425
vaginal, dryness therapy 491
estrogen(s)
atrophic vaginitis 301
bone effects 12
breast cancer and 351–352, **357–358**
endometrial cancer and 436
endometriosis and 315, 316
follicular phase and 34, 35
menopausal hot flushes and 427
ovulation and *36*
preterm labor/birth and 140
sexual dysfunction management 491
Turner syndrome and 383
vaginal flora/physiology and 294
see also specific hormones
estrogen–progestin contraceptives *see* combination pill
ethical issues 517–526
AMA Code of Ethics 517, 519, **519**
decision making guidelines 524–525, **525**
fetal reduction 175
fetus as patient 519–522
maternal autonomy *vs.* fetal beneficence 519–521
maternal autonomy *vs.* nonmaleficence 521–522
viability and 520
gender selection and 521
gynecological dilemmas 522–525
communicable disease 524
contraception in minors/non-competent individuals 523–524
therapeutic abortion 285, 522
HIV testing and results 520, 524
infertility 411
medical education and 517, 522
medical errors and 513
negative *vs.* positive patient rights 521
neonate as patient 522
principles of medical ethics 517–519, **518**
autonomy 518
beneficence 518
justice 519
nonmaleficence 518
'principalism' 517
third party rights 524
see also legal issues
ethnicity/race
chronic hypertension and 205
health issues and 3, *3*
maternal mortality and 234, *235*
menopausal symptoms and 425
European Society of Human Reproduction and Embryology (ESHRE), polycystic ovary syndrome criteria **387,** 387–388
evidence-based medicine, medical economics and 502
examination(s) 15–24
definitions 15–16
history *see* history taking
imaging *see* imaging
laboratory tests *see* laboratory evaluation(s)
physical *see* physical examination
see also specific aspects; specific conditions
exercise, birth to adolescence 5
expulsion (fetal) *103,* 104
extension (fetal) 101, *103*
external genitalia
anatomy 28, *28*
definition 25
embryogenesis 25, *26*
episiotomy and 28, *28*
inspection 18
see also specific structures
external rotation (fetal) 101, *103*
eye infection, neonatal prophylaxis 112

F

fallopian tube(s)
anatomy 29, *29*
common developmental abnormalities **25**
masses 484
cancer 483
cysts 483

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

tubo-ovarian abscess 313
see also adnexal masses
pregnancy in (tubal pregnancy) *see* ectopic pregnancy
family planning 275–284
contraception *see* contraception
medical economics and 501
psychiatric disorders and 241
sterilization *280,* 280–281
see also therapeutic abortion; *specific methods*
fat necrosis, breast 347, *348*
female condoms 277
female orgasm disorder (FAD) 490
female sexual arousal disorder (FSAD) 490
fertility
definition 403
life-style effects on 409
see also infertility
fertilization 37–38, 403, *403*
site 37, *37*
sperm penetration of ovum 37, *38*
zygote formation 37, 38
fetal alcohol syndrome 82, *82*
fetal attitude, labor/delivery and 101
fetal blood
direct sampling 51, *52,* 69
congenital syphilis detection 228
rhesus isoimmunization and 163
extraction from maternal circulation 51–52
transfusion, rhesus isoimmunization 163, *163,* 164
fetal cells, from cervix 52
fetal circulation 77–78
fetal distress
monitoring *see* fetal surveillance
uterine rupture and 196
fetal DNA, in maternal blood 52
fetal fibronectin (fFN), preterm labor/birth diagnosis 141–142, 179, **189**
fetal growth restriction (FGR) 180–181
asymmetric 181
common abnormalities 181
definition 180–181
diagnosis 181
history/chief complaint 184
physical examination 185–186
ultrasonography and 185–186, *186,* 188–189
epidemiology/prevalence 181
etiology/pathophysiology 180–181, 182–183, **183**
aneuploidy 182, *182*
congenital anomalies 182, 185
environmental/life-style factors 182–183
multiple gestations 182
nutritional deficiency 182
management 188–189
algorithm *189*
perinatal mortality 180–181
prenatal screening 181
symmetric 181, 188
fetal heart beats
multifetal pregnancy diagnosis/assessment 171–172
rate measurement *see* fetal heart rate (FHR)
fetal heart rate (FHR) 92–96
accelerations 91
transient (normal) 92, *93*
asphyxia/hypoxia relationship 95, *95,* 96, **98**
continuous electronic monitoring 96–97
decelerations 91
early 92, 94
late 94, *95*
severity classification 94
transient (normal) 92, 94–95
variable 94, *94–95*
decreased variability 92, *93*
definitions 91
interventions for altered FHR 97–98
clinical 97–98
operative 98
multiple births 176
normal variations 92, *92*
post-term fetus 267
sinusoidal pattern 95–96
as surveillance tool 91
fetal lie, labor/delivery and 101
fetal position, labor/delivery and 101, *102*
malposition, dystocia and 147
fetal presentation, labor/delivery and 101
multifetal pregnancy/birth 176–177, *177*
fetal pulse oximetry 97
fetal reduction 175, **178**
fetal size
labor/delivery and 101
post-term babies 266
restricted growth *see* fetal growth restriction (FGR)
fetal station, labor/delivery and 101, *102*
fetal surveillance 91–98
bradycardia 92
definitions 91
Doppler ultrasonography 96
fetal growth restriction and 185
heart rate *see* fetal heart rate (FHR)
intermittent auscultation 96, *96*
interventions 97–98
maternal vital signs and 91, 97
metabolic status assessment 97
multiple births 176
post-term pregnancy 267, 269
tachycardia 92
fetus
ethical issues concerning *see under* ethical issues
growth potential of 179
growth restrictions/low birth weight 179–190
consequences 179, *179*
epidemiology/prevalence 181
growth restriction *see* fetal growth restriction (FGR)
mortality/morbitity and 179
preterm birth and *see* preterm labor/birth
see also low birth weight; preterm/premature babies
hypoxia/acidosis risks 91
labor/delivery and *see* labor/delivery
maternal psychiatric disease and 242, 244, **244**
multifetal pregnancy pathophysiology *170,* 170–171, 174
physiology *see* maternal–fetal physiology
post-term delivery and 266, *266,* 268, 269
respiratory system 107
rhesus antigen zygosity assessment 159
rhesus isoimmunization and *see* rhesus isoimmunization
surveillance *see* fetal surveillance
viability, ethical considerations 520
see also entries beginning feto-/fetal; pregnancy
fibroadenoma, breast 346
fibrocystic breast disease 346
fibroids (uterine) *see* uterine leiomyomas
fibromas
ovarian 482–483
uterine *see* uterine leiomyomas
fibromyalgia, pelvic pain 326
FIGO *see* International Federation of Gynecology and Obstetrics (FIGO)
first trimester abortion 286–287, **287**
first trimester screening (FTS) 50–51, 66
second trimester screening *vs.* 67, *67*
see also specific methods
fissures, vulval lesions 449
flexion (fetal) 101, *103*
fluconazole, vulvovaginal candidiasis 298
fluorescence in situ hybridization (FISH), prenatal testing 52–53, *53*
folic acid, preconception care 85, **89**
follicle-stimulating hormone (FSH)
follicular phase of menstrual cycle 32, 33, 34, *34*
infertility treatment
ovarian hyperstimulation syndrome 410
in PCOS 393
oocyte pool analysis 404
perimenopause and 423, **424,** 426
follicular atresia, definition 31
follicular phase (menstrual cycle) *32,* 32–35
average length of 32
follicle development during 32, *33*
dominant follicle 34, *34*
preantral follicles 33–35
preovulatory follicle 35, *35*

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

primary follicles 32
primordial follicles 33, *33*
'two-cell, two-gonadotropin theory' 33–34, *34*
termination of 34, *34*
follistatin, follicular phase and 34
forceps delivery 105, *106*
forensic examination, sexual assault 497
fragile X syndrome 50, 426
fraternal dizygotic siblings, definition 167
fundal height
fetal growth restriction assessment 185
pre-eclampsia and 152

G

gabapentin, chronic pelvic pain management 328
galactocele 343
galactorrhea 344
galactosemia, primary ovarian failure 423
gamete(s)
definition 31, 41
fusion (fertilization) 37
gametocyte, definition 31
gastroesophageal reflux disease, pregnancy and
chief complaints/examination 258
etiology/pathogenesis and *256,* 256–257
laboratory evaluation/monitoring 259, *259*
management 262
gastrointestinal disorders
pelvic pain and **325,** 326
pregnancy and
chief complaints/examination 258
diagnosis 253–254
epidemiology/prevalence 254
etiology/pathogenesis and 255–257, *256*
laboratory evaluation 259–260
management 261–262
see also specific disorders
gastrointestinal motility disorders
definition 251
see also specific disorders
gender testing, ethical issues 522
gene, definition 41–42
gene expression, definition 42
generalized anxiety disorder (GAD) 246
generic medicines, medical economics and 502
genetic anticipation
autosomal dominant disorders 49
trinucleotide repeat disorders 49–50
genetics/genomics 41–56
basic concepts 42–43
cancer
breast cancer 352, 353
gynecological cancers 436, 472
chromosomes *see* chromosome(s)
definitions 41–42
diagnosis/management of genetic disorders 50–54
prenatal testing *see* prenatal testing
endometriosis and 315
impact on OB/GYN practice 42
Mendelian disorders 49
multifetal pregnancies and 169
non-Mendelian disorders 49–50
polygenic/multifactorial disorders 49
psychiatric disorders 242
see also individual genes; specific conditions
genital embryogenesis 25–27, *26*
abnormalities 25, **25,** *27*
definitions 25
genital herpes *see* herpes simplex virus (HSV)
genitalia 28–30
embryological development *see* genital embryogenesis
external *see* external genitalia
internal *25,* 26
see also specific structures
genital ridge 25
genital tubercle 25, *26*
genome, definition 42
genotype, definition 42
germ cell tumors **481,** 481–482
gestational age
determination 137
FGR diagnosis and 181, 185
infant mortality relationship 136
post-term pregnancy diagnosis 265
gestational diabetes 75, 251
diagnosis 253, **254**
epidemiology/prevalence 254
gestational hypertension
definition 203–204
diagnosis 204
pre-eclampsia and 204
prognosis 208
severe 204
treatment 207–208
non-pharmacological 207
pharmacologic therapy *see* antihypertensive pharmacologic therapy
see also pre-eclampsia–eclampsia syndrome
gestational trophoblastic diseases (GTDs) *see* molar pregnancy
gestational trophoblastic neoplasia (GTN)
definition 441
staging 443
treatment 444
see also specific tumors
glandular breast tissue 341, *341*
glucose metabolism
diabetes diagnosis 253
polycystic ovary syndrome and 391
pregnancy-related changes 75, **78–79**
antepartum care and 86
gonadotropin releasing hormone (GnRH)
agonists/analogues
pelvic pain management 319–320, **320**
PMS/PMDD management 418
uterine leiomyoma management 462–463
amenorrhea and
breast-feeding 343
secondary amenorrhea 379–380
polycystic ovary syndrome and 388
pulsatile release 319
gonorrhea 305, *305*
prophylactic treatment following sexual assault 497
granuloma inguinale 309
granulosa cells 32, 33, 36
granulosa–stromal cell tumors 482
group B streptococcus (GBS) 225–226
antepartum vaccination/prophylaxis 86–87, 226, *226*
preterm labor/birth management 142–143
PROM and 198
diagnosis 225
guidelines for prevention of neonatal GBS 143
management 225–226, **226**
maternal infection 225
neonatal infection 225, **226**
screening 143, 226, *226*
growth hormone therapy, Turner syndrome 383
gumma, late/tertiary syphilis 227–228, 306–307
gynecological surgery 363–385
approaches/methods
abdominal (laparotomy) approach 364
hysteroscopic approach 365–366
laparoscopic approach 364–365
vaginal approach 363–364
common procedures 366–375
D & C *see* dilation (dilatation) and curettage (D&C)
hysterectomy *see* hysterectomy
myomectomy 370–372, **371,** *372*
oophorectomy 353, 372–373
ovarian cystectomy *373,* 373–374
historical perspective 363
office procedures 374–375
robotic 371–372, 374
uterine atony management 216
see also specific techniques/procedures
gynecologic history 16, **17**

H

Haemophilus ducreyi 308
haloperidol, pregnancy and 246
haploid, definition 42
head growth, fetal growth restriction and 181
health care provision

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

patient–provider communication *see* communication
perinatal mortality and 233, *234*
social factors/economics 501–506
see also medical economics
Health Insurance Portability and Accountability Act (1996) 524, 531–532
health issues
ethnicity/race and 3, *3*
sex differences and 3, 8
health records
medical economics and 502
preventing harm and 531
heartburn, pregnancy and 256
heart disease, menopause and 11, 429
heart rate, fetal *see* fetal heart rate (FHR)
heat treatment, dysmenorrhea and 400
HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome 150, **150,** 152
hematogenous, definition 219
hemolytic disease 159, *159,* 161
non-D antibodies associated 160, **160**
see also rhesus isoimmunization
hemorrhage
cervical, punctate 300, *300*
hysterectomy complications 370
postpartum *see* postpartum hemorrhage
therapeutic abortion and 289
see also bleeding; *specific causes*
heparinization, pre-eclampsia/eclampsia and 155
hepatitis B virus (HBV) 309
preconception evaluation 84
herpes simplex virus (HSV) 307
clinical manifestations 222, **222,** *306,* 307, *307*
diagnosis 222
pregnancy and 222–223
perinatal transmission 222
treatment/prevention 223, **223,** *223,* 307
structure 222, *222*
transmission reduction in discordant couples **309**
treatment 223, **223,** *223,* 307, **308**
type 1 222, 307
type 2 222, 307
heterotopic pregnancy 124
hidradenitis suppurativa, vulval lesions 449
highly active antiretroviral therapy (HAART) 223, 224
hirsutism 394
management 394, *394*
polycystic ovary syndrome and 390
scoring system 390, *390,* 394
Sertoli–Leydig cell tumors 483
history taking 16–17, **17**
body language and 508, 509
chief complaint 16
chronic pelvic pain 326–327
dysmenorrhea 398–399
ectopic pregnancy and 120–122
endometriosis 316
fetal growth restriction 184
gynecologic 16, **17**
medical complications of pregnancy 257–259
menopause and 425–426
obstetric 17, **17**
open-ended questions 488, 508–509
patient-centered *vs.* clinician-centered approach 508
polycystic ovary syndrome and 389–390, 391, **392**
post-term pregnancy 267
preconception care and 81–83
pre-eclampsia–eclampsia syndrome 152
present illness 16
preterm labor/birth and 140, 184, *185*
PROM and 195
rhesus isoimmunization and 161–162, **162**
sensitivity/confidentiality 508
sexual *see* sexual history
sexual assault 497
spontaneous abortion 129–130
therapeutic abortion and 286
third trimester bleeding 195
vaginitis diagnosis 295
HIV infection/AIDS 309
antiviral drugs 223, 224
breast-feeding contraindication 224, 342
epidemiology 223
infection/life cycle 223
pregnancy and 223–225
antenatal testing 224, 520–521
antepartum measures 224, **225,** *225*
delivery route 224
management goals 223
maternal autonomy *vs.* fetal beneficence 520
postpartum measures 224
preconception care and 84
vertical transmission 224
prophylactic treatment/testing following sexual assault 497
transmission 224
virus structure *84,* 223, *224*
homicide, maternal mortality 496
hormonal contraceptive methods 277–279
breast-feeding and 343–344
contraindications/discontinuation **276,** 279
emergency contraception 281–282
formulations 277–278, **278**
IUDs and 277, 278, 463
mechanism of action 277
noncontraceptive benefits 279
endometriosis-related pelvic pain and 318–319, **319**
oligomenorrhea treatment in PCOS 392
PMS/PMDD treatment 418, **419**
uterine leiomyoma management 463
side effects/risks 278–279
breast cancer and 352
see also specific types
hormonal factors
breast cancer 351–352
endometriosis and 315, 316
hormone replacement therapy (HRT) 428–429
bone density and 428
breast cancer and 10–11, 352, 429
HRT in survivors 357
breast density effects 11, *11*
cardiovascular disease and 429
conjugated equine estrogen (Premarin) **430**
endometriosis and 321
estrogen *vs.* estrogen–progestin treatments **431**
future 429
hot flushes and 427–428
WHI study 429, **430**
hormone therapy
adenomyosis treatment 322
breast cancer prevention 352–353, **358**
breast cancer treatment 356
contraception and *see* hormonal contraceptive methods
endometriosis-related pelvic pain 318–321, **319, 320**
menopausal symptoms *see* hormone replacement therapy (HRT)
sexual dysfunction management 491–492, **493**
uterine leiomyoma management 7–8
hospitalization
pelvic inflammatory disease 312, **313**
pre-eclampsia management 153, **154**
preterm labor/birth 142, 174
third trimester bleeding 215
'hot flushes' 423, **425**
treatment **424,** 427–428
HPV *see* human papilloma virus (HPV)
human chorionic gonadotropin (HCG) 65
ectopic pregnancy and 119, 121, 123
heterotopic pregnancy 124
molar pregnancy and 442
prenatal testing 66
spontaneous abortion 129
human immunodeficiency virus *see* HIV infection/AIDS
human insulins, pregnancy and 261
human papilloma virus (HPV) 309
cervical neoplasia/cancer 309, 435–436, 453
etiopathogenesis and 454–455
condylomas 309, 448, 454, 456
DNA testing 61–62, 455–456
cytology and 456, **456**
sensitivity/specificity 62
see also Pap smear
E6 protein 435–436, 455

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

E7 protein 436, 455
epidemiology of infection 435, 454
immunosuppression and 454
oncogenic potential of different types 435, 454
preventative vaccination 4–5, 455, **459–460**
vaginal neoplasia/cancer 451
vulvar neoplasia/cancer 449–450, **452**
human rights, research subjects and 515
hydatidiform mole 441–444
complete 441, *441*, **442**, *442*, **444–445**
diagnosis/monitoring
HCG levels and 442, 443, **444–445**
history/examination and laboratory studies 442–443
ultrasonography 441–442, *442*
epidemiology/prevalence 441, 442
etiology/pathophysiology 441
risk factors 442
oncogenic potential 441
partial 441, **442**
pathology *441*, 442, **442**
staging 443
systemic effects 443
treatment 443–444, **444–445**
D & C 442, 443
false-positive serum HCG and 443–444
hydramnios (polyhydramnios), definition 167
hydrops fetalis 161
hyperbilirubinemia
definition 107
management 113
rhesus isoimmunization 161
risks 113, *114*
hyperemesis gravidarum 256
chief complaints/examination 258
laboratory evaluation 260
management 262
hyperprolactinemia
nipple discharge and 344
spontaneous abortion and 129
hypertension
endometrial cancer and 472
epidemiology/prevalence 204–205
pregnancy and *see* hypertension, in pregnancy
hypertension, in pregnancy 203–210
chronic (pre-existing) 203
complications **204**
diagnosis 204
epidemiology/prevalence 205
etiology/pathophysiology 205–206, **206**
heart enlargement *203*
management *see below*
pre-eclampsia and 150, 203, 204, 205
pre-eclampsia *vs.* *150*, 150–151
subclassification 204
classification of 203
definitions 203–204
diagnosis 204, 206
etiology/pathophysiology 205, **205**
gestational *see* gestational hypertension
high *vs.* low risk groups 206, **206**
laboratory evaluations 206, **206**
medical history 206
multifetal pregnancies and 170, 174
physical signs 206
pre-eclampsia (pregnancy-induced) *see* pre-eclampsia–eclampsia syndrome
prognosis 208
special concerns 208
transient 205, 208
treatment 207–208
consultations 207
diet 207
pharmacologic therapy *see* antihypertensive pharmacologic therapy
physical activity 207
hyperthermia, definition 107
hyperthyroidism
postpartum 6, 257
in pregnancy 6
chief complaints/examination 258–259
diagnosis 254
etiology/pathogenesis and 257
laboratory evaluation 260
management 262
hypoactive sexual desire disorder (HSDD) 489–490
hypocontractile uterus, dystocia 146
hypophysis, definition 31
hypothalamic dysfunction, secondary amenorrhea 379–380
hypothalamic–pituitary–adrenal (HPA) axis
preterm labor/birth and 139–140, **148**
puberty role 4, 31
hypothalamus
menstrual cycle control **378**
thermoregulatory transition and 109, *110*
hypothermia, definition 107
hypothyroidism
postpartum 6, 257
preconception care and 84
in pregnancy 6
chief complaints/examination 258
diagnosis 254
etiology/pathogenesis and 257
laboratory evaluation 260
management 262
hypoxemia, definition 91
hypoxia
definition 91
fetal
assessment of 91
late decelerations (FHR) and 94, *95*
hysterectomy 366–370
adenomyosis treatment 322
alternatives 366
approaches 366–370, **367**
abdominal (laparotomy) 366–367, *368*
laparoscopic 369–370
relative merits 368
vaginal 367–368, *369*
see also specific techniques
cervical cancer therapy 457
chronic pelvic pain management 328, **328–329**
complications 370
historical aspects 363
indications 366
rates 366
supracervical *vs.* total 367, **375**
uterine leiomyoma management 7, **468**
hysterosalpingogram, infertility diagnosis/evaluation 405
hysterosalpingography 21–22, *22*
hysteroscopy 23, *23*, 365–366
office setting 375
pain 375
principles 365, *365*
tubal ligation 281, *281*, 365
uterine leiomyomas 462
vaginoscopic approach 375

I

identical monozygotic siblings, definition 167
imaging 21–23
adenomyosis 322
diagnostic value, best evidence **24**
endometriosis diagnosis 7
prenatal screening tests 51
see also specific techniques
immune system
cancer cells and 438
endometriosis and 315
isoimmunization, rhesus antigens *see* rhesus isoimmunization
preterm labor/birth 139
see also specific components/processes
immunoglobulin G (IgG), rhesus isoimmunization and 162–163
immunoglobulin M (IgM), rhesus isoimmunization and 162–163
imprinting disorders 50
isochromosomes and 48
incompetent cervix *see* cervical insufficiency
incomplete abortion
definition 127
therapeutic abortion 288–289
incontinence (urinary) *see* urinary incontinence
incubators 112, *112*
indomethacin, as tocolytic agent 188
inevitable abortion, definition 127
infanticide, maternal psychiatric illness and 242
infant mortality
gestational age relationship 136

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

low birth weight and 179
maternal psychiatric illness and 242
preterm birth and 136, *136*
infections/infectious disease
bacterial *see* bacterial infections
cervical cancer and *see* human papilloma virus (HPV)
definitions 219
hormonal contraception and 279
hysterectomy complications 370
IUDs and 280
pelvic inflammatory disease *see* pelvic inflammatory disease (PID)
pregnancy and 219–232
bacterial infections 225–229
fetal growth restriction and 182
maternal mortality and 238
postpartum endometritis *see* puerperal endometritis
preconception care and 84
preterm labor/birth and 137–138, **138,** 193, 236
protozoan infections 229–231
spontaneous abortion and 129
viral infections 219–225
protozoan *see* protozoan infections
therapeutic abortion and 288
urinary tract 336
viral *see* viral infections
see also specific organisms/infections
infertility 403–415
definition 403
diagnosis/evaluation 404–405
anovulation and 407
hysterosalpingogram 405
laparoscopy 405, 407
oocyte pool assessment 404
outdated tests 405
ovulation tests 404
semen analysis 404–405, **405**
standard evaluation 392
unexplained infertility 407
epidemiology 403
ethical issues 411
etiology/pathophysiology *403,* 403–404, 409
anovulatory cycles 392–393, 407
breast cancer therapy 356–357
cervical factors 408
endometriosis 7, 318, *319,* 408
IUDs and 280, **282**
life-style factors 409
male factors 406
pelvic inflammatory disease and 311
polycystic ovary syndrome and 392, 407
stress and 411
therapeutic abortion association 289
tubal factors 406
uterine factors 408
psychosocial aspects 411
social issues 411
treatment 406–408
adoption and 411
anovulatory infertility 407
ART *see* assisted reproductive technology (ART)
cervical factors 408
endometriosis 408
male factors 406
ovarian hyperstimulation syndrome and 410–411
ovulatory timing and **412**
polycystic ovary syndrome and 392–393, **393, 395,** 407
stepwise approach 407, **408**
tubal factors 406
unexplained infertility 407
uterine factors 408
see also specific causes
inflammation
intrauterine, preterm labor/birth and 137–138
mastitis 343, 346, 347
informed consent 510–511, **510–511,** 529
inhibins 65
follicular phase and 34
instrumental vaginal delivery 98, 105, *106*
insulin resistance
endometrial cancer and 471
polycystic ovary syndrome and 389, *389,* 390, 391
infertility and 392–393
insulin treatment, pregnancy and 261
integrated prenatal screening (IPS) 51, *67,* 67–68
best evidence **54**
contingent sequential testing 68
stepwise sequential testing 68
internal genitalia
definition 25
embryogenesis 25, *26*
see also specific structures
internal rotation (fetal) 101, *103*
International Federation of Gynecology and Obstetrics (FIGO)
cervical cancer staging system **454,** 457, *458,* **459**
endometrial cancer staging system 473, **473**
ovarian cancer staging system 479–480, **480**
International System for Human Cytogenetic Nomenclature (ISCN) 42–43
interoperable national health record, medical economics and 502
interstitial cystitis 326
interstitial (cornual) pregnancy 124, **125**
intertwin membrane 172–173
thickness 168
intracytoplasmic sperm injection (ISI) 406
intrapartum care
fetal surveillance *see* fetal surveillance
interventions for altered heart rate 97–98
see also specific interventions/procedures
intrauterine adhesions, secondary amenorrhea 382
intrauterine device (IUD) 279–280
approved types 279
contraindications 280
hormonal 277, 278
uterine leiomyomas and 463
mechanism of action 279
risks/side effects 280
infertility and 280, **282**
pelvic inflammatory disease 311
intrauterine insemination (IUI) 406
intrauterine scar tissue, secondary amenorrhea 382
invasive mole 443
inversions 47
in vitro fertilization (IVF)
indications 409–410
infertility treatment in PCOS 393
key steps 409, *409*
iron deficiency anemia, postpartum outcomes 237
iron supplements 237
irritable bowel syndrome (IBS), pelvic pain and 326
isochromosomes 48
isoimmunization, rhesus antigens *see* rhesus isoimmunization

J

jaundice
neonatal care 113, *114*
rhesus isoimmunization and 161
justice 518, **518**

K

karyotype, definition 42
karyotyping 128, *128*
prenatal testing 52, *52,* 68, *68*
Kegel exercises 334–335
kidney(s), maternal changes during pregnancy 76
Klebsiella granulomatis 308
Klinefelter syndrome (47,XXY) 45–46, *46*

L

labetalol, severe postpartum hypertension **208**
laboratory evaluation(s) 19–21
biopsies 20–21
chronic pelvic pain 327
definitions 15–16
dysmenorrhea 399
ectopic pregnancy 119, 121
endometriosis 317
glucose screening 86
hypertension in pregnancy 206, **206**
pre-eclampsia 152, **153**

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

medical complications of pregnancy 259–260
menopause and 426
multifetal pregnancy 173
neonatal care 113
Papanicolaou test *see* Pap smear
polycystic ovary syndrome and 391
prenatal testing 52–53
preterm labor/birth and 141–142, 179, **180,** 186, **189**
PROM and 191, 196–197
rhesus isoimmunization diagnosis 162–164
serological *see* serological evaluation
sexual assault 497
therapeutic abortion and 286
third trimester bleeding and 197
vaginitis diagnosis **295,** 295–296
bacterial vaginosis 299, *299*
vulvovaginal candidiasis *296,* 296–297
see also specific tests
labor augmentation, definition 146
labor/delivery 99–106
definition 145–146
episiotomy and 28, *28,* 105, *105,* **106**
fetus and
cardinal movements 101, *103,* 104
fetal characteristics and effects on 101, *102*
surveillance *see* fetal surveillance
see also neonatal period
induction
ACOG guidelines 234
multifetal pregnancy 176
post-term pregnancies *268,* 268–269
pre-eclampsia/eclampsia management 153, 155
PROM management 198
therapeutic abortion 288
mechanics 99–101
contraction parameters 99–100
pelvis and *100,* 100–101
multiple births *see* multifetal pregnancy
operative/instrumental vaginal delivery 98, 105, *106*
partograph (partogram) 237, *237*
pathological 135–148
definitions 135, **145,** 145–146
difficult/prolonged *see* dystocia
obstructed 237–238
preterm *see* preterm labor/birth
see also post-term pregnancy
phases 99, 104, *104,* 147
physiologic aspects 99, *99*
prevention *see* tocolytic therapy
progress **104,** *104,* 104–105
stages 104
dystocia management 147–148
normal *vs.* abnormal progress 146
'three P's' 135
urinary incontinence and 333
lactation 341, 342
disorders associated 343
see also breast-feeding
lactobacilli, normal vaginal flora 294
lactogenic hormones 342
lambda sign 172
laminaria tents 287, *288*
laparoscopically assisted myotomy (LAM) 466
laparoscopic morcellator 465–466
laparoscopic myolysis 467
laparoscopic uterine artery occlusion (LUAO), uterine leiomyomas 466
laparoscopy 23, 364–365
ectopic pregnancy management 122, 125
endometriosis
diagnosis 7
treatment 321, **322, 323**
hysterectomy 369–370
infertility diagnosis/evaluation 405, 407
laparotomy *vs.* **364,** 364–365, 369–370
method 364, *365*
ovarian cystectomy 373
post-operative effects/recovery 365, 370
tubal ligation 281, *281*
uterine nerve ablation, dysmenorrhea and 401
laparotomy 364
ectopic pregnancy management 122
hysterectomy and 366–367
laparoscopy *vs.* **364,** 364–365, 369–370
latency, definition 219
latent phase (labor) 104, **104,** *104*
late pregnancy bleeding *see* third trimester bleeding
lean engineering, medical economics and 502
legal issues 527–533
adverse outcomes and *see* adverse outcomes
breaches of duty 530
causation 530
certification 528
common areas of increased liability risk 530–531
communication importance 528, 530
credentialing 528
damage done 530
disclosing medical errors 513, 529
documentation 531
Health Insurance Portability and Accountability Act 524, 531–532
informed consent 510–511, **510–511,** 529
lawsuit effects on OB/GYN practice 527, **527**
licensure 528
maternal autonomy *vs.* fetal beneficence 520
negligence 530
privileges 528
risk management 530
standards of care 528
therapeutic abortion 285
see also ethical issues
leiomyomas, uterine *see* uterine leiomyomas
leiomyosarcomas, uterine 474–475
levonorgestrel-releasing intrauterine system 401
licensure 528
lichen planus, vulvitis 302–303
lichen sclerosus, vulvitis 302
lichen simplex chronicus, vulvitis 302
life-style
fertility/infertility and 409
fetal growth restriction and 182–183
pregnancy and preconception care 82, **82,** *82,* **83**
premenstrual syndrome 417–418
urge incontinence management 335–336
see also specific factors
Liley curve 163, *163*
lipoma, breast 347
listeria 238
lithotomy 18, *18*
LNG-20 (Mirena) IUD 279
lobular carcinoma in situ 347
lobular-type epithelial proliferation 347
'locked twins' 177, *177*
longevity
medical economics and 501
poor *vs.* wealthy countries 505
see also mortality
low birth weight 179–190
consequences 179, *179*
definition 135
therapeutic abortion association 289
see also fetal growth restriction (FGR); preterm/premature babies
lubricants, vaginal dryness and 491
lung function
asthma diagnosis 252, *252*
maternal changes during pregnancy 76, *76*
lung maturation 107
antenatal steroids and *see* steroid-induced lung maturation
luteal cells 36
luteal phase (menstrual cycle) *36,* 36–37
luteinizing hormone (LH)
follicular phase and 34, *34,* 35
luteal phase and 36
ovulation and 35
home testing, best evidence **38**
polycystic ovary syndrome and 391
luteolysis 37
lymphadenectomy
cervical cancer therapy 457
endometrial cancer and 474
lymphadenopathy
definition 219
syphilis 227
lymph nodes

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

breast cancer involvement **355,** *355,* 355–356
breast examination 341
lymphogranuloma venereum (LGV) 308, **308**
Lynch syndrome 436
endometrial cancer and 436, 473

M

macroprolactinomas, treatment 381
magnesium sulfate
pre-eclampsia and 236
as tocolytic **186,** 187
magnetic resonance imaging (MRI)
adenomyosis diagnosis 322
breast cancer screening 354, *354*
uterine leiomyomas
diagnosis 371, 462
MRI-guided focused ultrasound therapy 467
malaise, definition 219
male(s)
age-related changes in sexual activity 492
breast cancer 351
condoms 277
females *vs. see* sex differences
infertility treatment 406
sexual dysfunction 488, **488**
sexual responses 487–488
sterilization (vasectomy) 281
mammography
age effects 345
breast cancer screening 353–354, *354*
breast mass evaluation/diagnosis 345, 354
fat necrosis and 347, *348*
HRT effects 11, *11*
marsupialization of Bartholin cyst 447, *447*
mastalgia 344
mastectomy, risk reducing bilateral 353
mastitis 343, 347
chronic cystic 346
maternal age
adolescent pregnancy 5, 81
chronic hypertension and 205
ectopic pregnancy 119
mortality rates and 234–235
older mothers 82, 128
Edwards syndrome (trisomy 18) 45
multifetal pregnancies 169, 174
trisomy 13 (Patau syndrome) 44
trisomy 21 (Down syndrome) and 44, *44,* 65, 68
preconception care and 81–82
spontaneous abortion and 128
therapeutic abortion risk 286
maternal blood count, PROM diagnosis 197
maternal–fetal physiology 75–80
fetal physiology 77–78
amniotic fluid 78
endocrinology 78, *78*
fetal circulation 77–78
maternal physiology 75–77
carbohydrate metabolism 75, **78–79,** 86
cardiovascular system *75,* 75–76
labor 99, *99*
placental *see* placenta
renal function 76
respiratory system 76, *76*
maternal mortality 233–240
definition 233
epidemiology 234–235, *235*
etiologies *234,* 234–235
ectopic pregnancy 122, 125
infectious 238
iron deficiency 237
obstructed labor and 237–238
postpartum hemorrhage 213, 236
pre-eclampsia/eclampsia 149, 236
third trimester bleeding 191, 236–237
homicide and 496
maternity service provision and 505
prevention 236–238
antepartum care and 236
infection control 238
iron supplementation 237
magnesium sulfate 236
partograph and 237, *237*
symphysiotomy and 237–238
uterogenic agents 236–237, **239**
therapeutic abortion risk 286
see also specific causes
maternity services, reduction of mortality and 505
mechanical stimulators, sexual dysfunction 491
meconium
fetal metabolic status and 97
post-term fetus and inhalation 266, 269
meconium aspiration syndrome 269
medical abortion 286–287, **287, 290**
medical documentation 531
medical economics 501–506
developed countries and 501–505
chronic illness management 503
ending of per-case payments 503–504
evidence-based medicine 502
generic medicines and 502
health care costs as percentage of GDP 501, *502*
improving quality 504, **504–505**
interoperable national health record 502
intervention in last weeks of life 503
preventative medicine 503, **503**
professional liability reform 504
rationing health care 504
regional variations and best practice **506**
waste reduction (lean engineering) 502
developing/poor countries 505
health disparities 505
population health effects on economic growth/stability 501
rapidly growing economies 505
medical education
ethical issues and 517, 522
legal issues and 532, *532*
medical errors, disclosing 513, 529
medical ethics *see* ethical issues
medical research, human rights 515
meiosis 42, *43*
melanocytic nevi, vulval lesions 448
melanoma, vulval lesions 448
membrane sweeping/stripping 268, *268*
men *see* male(s)
menarche 4, 31, 382
age at
breast cancer and 351
factors affecting 423
definition 15–16, 31
Mendelian genetics 41, 49
disorders 49
see also specific types
menometrorrhagia, definition 384
menopausal transition 421–422
menopause 10–12, 421–431
age of onset 10, 421, 423
breast cancer and 351
factors affecting 423
breast cancer and HRT 10–11
breast cancer survivors 357
clinical presentation/features 10, 425–426
cognition and 426
endometriosis and 321
heart disease 11, 429
hot flushes 423, **424,** 425, 427
laboratory evaluations 426
mood disorders 426
osteoporosis 12, *12,* 428
physical examination 426
racial differences 425
sexual dysfunction 425–426
urinary incontinence 12, *12,* 426
vaginal symptoms 301, 425, 428
see also specific symptoms
definition 422
etiology/epidemiology 423
physiology 423
premature *see* premature ovarian failure
surgical 427
treatments 427–429
bone density and 428
breast cancer and 429
cardiovascular system and 429
hot flushes **424,** 427–428
vaginal symptoms **424,** 428
see also hormone replacement therapy (HRT)

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

see also perimenopause; postmenopause
menorrhagia, definition 384
menorrhea, definition 31
menses
definition 31
initiation *see* menarche
see also menstruation
menstrual cycle 31–40, 378
absence *see* amenorrhea
bleeding *see* menstruation
breast-feeding and 343
definitions 31
hormonal contraception and 279
hypothalamic control **378**
initiation (menarche) *see* menarche
irregularity and the menopause 425
see also menopause
normal lengths 384
phases *32,* 32–37
follicular *see* follicular phase (menstrual cycle)
luteal phase *36,* 36–37
ovulation 35–36, *36,* **38**
see also fertilization
polycystic ovary syndrome and 389
premenstrual syndrome *see* premenstrual syndrome (PMS)
vaginal discharge and 294
see also specific phases
menstruation
abnormal bleeding 384–385
absence *see* amenorrhea
definition 16
painful *see* dysmenorrhea
mental health issues 8–9
following sexual assault 497
see also psychiatric disorders; *specific disorders*
mesosalpingeal cysts 483
metabolic acidosis, definition 91
metabolic disorders
polycystic ovary syndrome and 388–389, **389,** *389,* 390, 391
see also specific disorders
metabolic rate, neonatal period 110
metabolic status, fetal monitoring 97
metabolic syndrome, polycystic ovary syndrome and 388, **389**
metformin, anovulatory infertility treatment in PCOS 392–393, **395**
methotrexate, ectopic pregnancy management 122–123
adverse effects 123, **124**
efficacy 123
indications/contraindications 123, *123*
protocols 123
metronidazole, trichomoniasis treatment 301
metrorrhagia, definition 384
microprolactinomas, treatment 380–381
microsatellite instability 49–50
midpelvis 101
mifepristone, medical abortion 286–287, **287**
'milking,' ectopic pregnancy management 122
Mirena (LNG-20) IUD 279
miscarriage *see* spontaneous abortion
mismatch repair (MMR) genes, cancer and 436, 472, 479
misoprostol
postpartum hemorrhage management 236–237, **239**
spontaneous abortion management 130
therapeutic abortion and 288
missed abortion, definition 127
mitochondrial disorders 49
mitosis 42, *43*
moisturizers, vaginal dryness and 491
molar pregnancy 441–446
benign *see* hydatidiform mole
definition 127, 441
dilation (dilatation) and curettage 442, 443
HCG levels and 442, 443
false-positives 443–444
malignant *see* gestational trophoblastic neoplasia (GTN)
staging 443
systemic manifestations 443
see also specific tumors
molluscum contagiosum, vulval lesions 448
monosomies 44, 46–47
isochromosomes and 48
see also specific disorders
monosomy X (45,X; Turner syndrome) *see* Turner syndrome
monozygotic siblings
definition 167
twin birth rate 168
Montevideo unit 100
mood disorders, menopause and 426
mood stabilizers, breast-feeding and 248
moral rules 519
moral theories **518**
morning-after pill 281–282
following sexual assault 497
morning sickness 256
mortality 233–240
definitions 233
developing countries 505
maternal *see* maternal mortality
perinatal *see* perinatal mortality
poor *vs.* wealthy countries 505
third trimester bleeding and 191
mosaicism
definition 42
placental 68
Müllerian duct
anomalies
common types 25, **25,** *27*
definition 16
embryogenesis 25, *26*
multichannel urodynamics 333–334
multifactorial inheritance 49
multifetal pregnancy 167–178
definitions 167
diagnosis/assessment 168, *168,* 171–173
amnionicity 168, 172, *172*
caveats 172–173
chorionicity *see* chorionicity
history/chief symptoms 171
laboratory evaluations 173
physical examination 171
ultrasonography 168, *168,* 171–173, *172, 173*
epidemiology 168, **169**
etiology 169–170
ART and 168, 169–170, 410
genetics 169
maternal age and 169, 174
fetal physiology/pathophysiology *170,* 170–171, 174
fetal growth restriction and 182
higher-order pregnancies 168
biophysical profiles 174
labor/delivery 178
labor/delivery 175–178
anesthesia 176
duration 176
fetal monitoring 176
induction/stimulation 176
'locked twins' 177, *177*
mode of delivery 176–177
preterm labor/birth and 136, 139, 174–175
see also preterm labor/birth
preventing potential complications 175–176
timing interval between deliveries 177
timing of 177
vertex–nonvertex delivery 177
vertex–vertex delivery 176–177
management 173–175
antepartum 173–174
fetal reduction 175, **178**
preterm labor prevention *see under* preterm labor/birth
maternal physiology/pathophysiology 170, 174
see also twins
multiple birth
definition 167
see also multifetal pregnancy
multistep carcinogenesis 437
musculoskeletal system, pelvic pain and **325,** 326
myalgia, definition 219
myofascial pain syndromes, pelvic pain 326
myomas
definition 16
see also uterine leiomyomas
myomectomy 370–372, 464–466
embolization/occlusion *vs.* **468**
indications 371, **371**
laparoscopic suturing as limiting factor 464, 466

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

procedure 371–372, *372, 464–465,* 465–466
as treatment of choice 463
myometrium 28
adenomyosis and 321

N

National Commission for the protection of Human Subjects of Biomedical and Behavioral Research 515
National Institutes of Health (NIH), polycystic ovary syndrome criteria 387, **387**
National Research Act (1974) 515
National Surgical Adjuvant Breast and Bowel Project (NSABP) 352–353
natural family planning 276
nausea, pregnancy-related (morning sickness) 256
negligence 530
Neisseria gonorrhoeae 305, *305*
neonatal care 110–113
breast-feeding/nutrition 112, **114**
see also breast-feeding
definitions 107
discharge procedures 113
ethical dilemmas 522
evaluation and resuscitation 110–111
general care 111
home routines 113
identification and security 111
initial physical assessment/prophylaxis 112
jaundice management 113, *114*
laboratory evaluations 113
respiratory care 107–108, *111*
Apgar score 107, 108, 110, **110**
evaluation and resuscitation 110–111
stooling 113
thermal regulation 111–112
incubators 112, *112*
voiding micturition 113
neonatal period 107–115
breast tissue 344
care during *see* neonatal care
circulatory transition 108, *109*
definition 107
drug toxicity/withdrawal and, antidepressants 245, **245**
maternal psychiatric illness and 242
metabolic rate 110
mortality *see* perinatal mortality
respiratory transition 107–108
sepsis, GBS and 225
thermoregulatory transition 108–110
heat loss/gain 110
hypothalamus and 109, *110*
neonatal thermoregulation 108–109
thermal neutral zone 109, *109*
thermoregulatory behaviors 110
neural tube defects (NTDs)
multifactorial inheritance 49
screening 69
neuraxial anesthesia
abnormal labor and 146–147
multifetal pregnancy/birth 176
neuroleptics (antipsychotic drugs)
breast-feeding and 248
pregnancy and 246
neuropathic pain 326
management 328
newborn care *see* neonatal care
newborns (neonates) *see* neonatal period
nifedipine, dysmenorrhea treatment 401
nipple(s) 341, *341*
accessory 344
discharge *343,* 344
nitrazine test 191
nitroimidazole, trichomoniasis treatment 301
nociceptive pain 326
noncoital nonsexual pain disorder 490
nonmaleficence 518, **518**
non-Mendelian disorders 49–50
non-steroidal anti-inflammatory drugs (NSAIDs)
dysmenorrhea treatment 400, **400**
pelvic pain and endometriosis management 318–319
nonstress test, post-term pregnancy 267
nontubal ectopic pregnancy 124–125, **125**
nuchal translucency 51, 66, *66*
definition 65
nutrition
antepartum care and 87
birth to adolescence 5
breast-feeding and
benefits to newborn 112
mother 9–10
fetal growth restriction and 182
hypertension management 207
infertility and 409
multifetal pregnancy and 173
pregnancy, diabetes and 261
reproductive age women and offspring 9–10, **10**

O

obesity
birth to adolescence 5
endometrial cancer and 471, 472
fertility and 392, 409
morbid, definition 393
polycystic ovary syndrome and 390
infertility and 392
management 392, 393
pregnancy risks 87
obsessive compulsive disorder (OCD) 9, 246
obstetric history 17, **17**
obstetric practice
lawsuit effects on 527, **527**
preterm labor/birth and 136, *137,* 182
see also specific components
obstructed labor, maternal mortality/morbidity 237–238
office-based procedures/surgery 374–375
vaginitis diagnosis **295,** 295–296
oligomenorrhea
differential diagnosis 389
tests/evaluation 404
treatment in PCOS 392
oligo-ovulation, polycystic ovary syndrome 390, 392
oncogenes 437
oocyte 32
changes in number during lifetime 421, *421, 422*
definition 31
pool evaluation 404
oocyte maturation inhibitor (OMI) 32
oogonia
definition 31
developmental changes 32
oophorectomy 372–373
bilateral
PMS/PMDD management 418
risk reducing (cancers) 353, 373
indications 373
operative vaginal delivery 98, 105, *106*
oral contraceptive pills (OCPs) 278, **278**
breast cancer risk 352
oral diabetic drugs, pregnancy and 261
orgasm, disorders 490
osteoporosis
breast cancer survivors and 357
diagnosis 12
management 12, *12*
menopause and 12, 428
ovarian cancer
diagnosis
germ cell tumor markers **481**
history/physical examination 479
postmenopausal women 477–478
premenopausal women 477, **478**
serum CA-125 477–478, 479
surgical–pathological 479–480
ultrasound 477, 479
endometrial cancer and 474
epidemiology 478, 479
epithelial 478–480
FIGO staging 479–480, **480**
germ cell tumors **481,** 481–482
management
chemotherapy 480
combined surgical/adjuvant approach **483**
optimal surgical cytoreduction 480
risk-reducing surgery **438,** 481
metastatic 481
pathology/pathogenesis
BRCA1/BRCA2 mutations 437, **438,** 479

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

germ-line mutations in MMR genes 436, 479
histological subtypes 477, *477,* 478–479
metastatic potential 480
risk factors 479
pregnancy and 480–481
sex cord–stromal tumors 482–483
survival rates by stage **480**
tumors of low malignant potential (borderline tumors) 478
see also specific types
ovarian cysts
'dermoid' (teratomas) 481
differential diagnosis in premenopausal women 477, **478**
endometriosis and 316, 317–318
epidemiology 477
laparoscopic removal *373,* 373–374
structures giving rise to 477, *477*
see also polycystic ovary syndrome (PCOS)
ovarian fibromas 482–483
ovarian hyperstimulation syndrome (OHSS) 410–411
ovarian hyperthecosis, virilization and 394
ovarian torsion 478
ovary(ies)
aging 421–431
clinical presentation 425–426
definitions 421–422
factors affecting 423
key stages 421–422, **422**
oocyte numbers and 421, *421, 422*
physiology 423–424
see also menopause; perimenopause; postmenopause
anatomy 29
common developmental abnormalities **25**
dysfunction
amenorrhea and 381
polycystic ovaries *see* polycystic ovary syndrome
primary (premature) failure *see* premature ovarian failure (POF)
see also infertility; *specific conditions*
ectopic pregnancy 125
hyperstimulation syndrome 410–411
masses 477–483
cysts *see* ovarian cysts
epithelial 478–480
evaluation 477–478
germ-cell tumors **481,** 481–482
histological subtypes 477, *477*
malignant *see* ovarian cancer
ovarian torsion 478
sex cord–stromal tumors 482–483
see also specific types
see also entries beginning ovarian
overflow incontinence 333
ovulation 35–36
home testing, best evidence **38**
infertility management and timing assessment **412**
polycystic ovary syndrome and 390
regulation *36*
testing 404
ovum, blighted 127
oxytocin
dystocia management 147
inhibitors, preterm labor prevention 188
uterine atony management 216, **216**
uterine rupture risk 194

P

p53
HPV effects 436, 455
type II endometrial cancer and 472
pain
abdominal *see* abdominal pain
assessment 327, *327*
back pain *see* back pain
breasts (mastalgia) 344
endometrial biopsy 375
neuropathic 326, 328
nociceptive 326
office hysteroscopy 375
ovarian torsion 478
pelvic *see* pelvic pain
sexual dysfunction and 490
uterine leiomyomas 462, 463
see also specific types/locations
palpation
abdominal examination 18, *18*
definition 16
pancreas, fetal 78
Papanicolaou test *see* Pap smear
papilloma, breast 346
Pap smear 19–20, 57–64
abnormal appearance *60*
Auto-Pap Screening System 20
bacterial vaginosis and 299
best evidence for effectiveness **62–63**
conventional 20, 59, *59*
liquid-based (ThinPrep) 20, *59,* 59–60
normal appearance *59*
sample collection/technique 20, 59, *59*
screening guidelines 61, **61**
sensitivity/specificity **60,** 60–61, **61**
terminology **57,** 57–58, **58**
detection rates and 61, **61**
trichomoniasis and 301
Paragard (TCu380A) IUD 279
parathyroid hormone (PTH), bone density effects 428
paresthesia, definition 219
partial hydatidiform mole 46–47
partograph (partogram) 237, *237*
parturition *see* labor/delivery
Patau syndrome (trisomy 13) 44–45, *45*
paternal rhesus antigen zygosity assessment 159
patient care 3–72
communication between patient–provider *see* communication
definition of OB/GYN care 3
genetic aspects *see* genetics/genomics
importance of 3
life-long 3–14
birth to adolescence 4–5
menopause 10–12
reproductive years 5–10
see also specific aspects
patient explanatory model 513–514
patient–provider communication *see* communication
PCOS *see* polycystic ovary syndrome (PCOS)
pedigree, definition 42
pelvic examination 18, *18*
ectopic pregnancy 120
preterm labor 184
pelvic inflammatory disease (PID) 311–314
clinical features 311
definition 311
diagnosis 312, **312**
etiology/pathophysiology 311
long-term consequences 311
see also infertility
risk factors 311
treatment 312–313
in-patient *vs.* outpatient 312, **313**
regimens **312**
tubo-ovarian abscess 313
see also sexually transmitted diseases (STDs); *specific causes*
pelvic inlet 100–101
pelvic organs
normal anatomy *332*
prolapse 331–332, *332*
see also specific organs
pelvic outlet 101
pelvic pain
assessment 327, *327*
chronic 325–330
definition 325
epidemiology/prevalence 326
history 326–327
laboratory studies 327
physical examination 327
diagnosis 325
etiologies 325, **325**
ectopic pregnancy 119
endometriosis 315, 316, 318–321
IBS 326
musculoskeletal 326
pelvic inflammatory disease 311
urinary tract 326
see also specific causes
management 327–328
aromatase inhibitors 320
combined hormonal/surgical 321
cyclic hormonal contraceptives plus NSAIDs 318–319
danazol 320
GnRH analogues 319–320, **320**
interdisciplinary pain practice 328

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

neuropathic pain 328
noncyclic combination contraceptives 319
progestin-only contraceptives 319, **319**
surgical 321, **323,** 328, **328–329,** 373
menopause effects 321
pathophysiology 326
pelvic relaxation 331–332, *332*
pelvimeter 100, *100*
penetrance, genetic disorders 49
penicillin
GBS management 225–226
syphilis management 229, 307
per-case payments 503–504
perimenopause 421–431
definition 422
physiology 423
prevention of FSH oscillation in 423, **424**
symptoms/signs 425–426
see also menopause; postmenopause
perinatal mortality 108, *108,* 233–240
definitions 233
early 233
epidemiology 233–234, *234*
etiologies 233–234
fetal growth restriction and 180–181
preterm/premature babies 136, *136,* 233, *234,* 235
see also specific causes
late 233
management/prevention 235–236
prenatal care role 236
preterm labor and *see under* preterm labor/birth
maternal psychiatric illness and 242
post-term pregnancy and 268
rate 233
periods *see* menstruation
peristalsis 255, *256*
peritoneal lining metaplasia, endometriosis and 315
persistent genital arousal disorder (PGAD) 490
persistent occiputoposterior position (POP), dystocia and 147
phenotype, definition 42
phyllodes tumor 346
physical assessment, dysmenorrhea 399, *399*
physical examination 17–19
abdominal examination 18, *18*
back pain assessment 252, *252*
bimanual examination 19, *19*
breasts 341–342
chronic pelvic pain 327
ectopic pregnancy 120
endometriosis 316, *316*
external genitalia inspection 18
fear/anxiety associated 17
fetal growth restriction 185–186
medical complications of pregnancy 257–259
menopause and 426
pelvic examination 18, *18*
pelvic inflammatory disease (PID) 312
postpartum hemorrhage 214–215
post-term pregnancy 267
pre-eclampsia–eclampsia syndrome 152
preterm labor/birth and 141, 184–185
PROM and 195–196
rectovaginal examination 19, *20*
rhesus isoimmunization diagnosis 162
sexual assault 497
sexual dysfunction and **489**
speculum examination 18–19, *19*
spontaneous abortion 130
therapeutic abortion and 286
third trimester bleeding 196
vaginitis diagnosis 295
see also specific aspects
physical therapy, sexual dysfunction 491
Pinard stethoscope 96, *96*
Pipelle biopsy 21, *22*
Piper forceps *106*
pituitary dysfunction, secondary amenorrhea 380–381
placenta 76–77
compartments 77, *77*
development 76, *76*
inner layer 76–77
late decelerations in FHR and 95
outer layer 77
preterm labor/birth and 139
spontaneous abortion and 129
tumors *see* molar pregnancy
see also specific disorders
placenta acreta
definition 211
delivery and 215
diagnosis 212
epidemiology/prevalence 212
etiology/pathophysiology 213, *213*
risk factors 213
therapeutic abortion and 289
placental abruption
classification/grading 193, 211
definition 191, 211
diagnosis
history/chief complaint 195, *195*
physical examination 196
epidemiology/prevalence 192, 212
etiology/pathophysiology 193, 213
management 199
delivery and 215
types/locations 215
placental insufficiency, pre-eclampsia and 205
placenta previa
classification/grading 193, *194,* 211, *211*
definition 191, 211–212
diagnosis 212, 214
history/chief complaint 195
physical examination 196, 214
ultrasonography 214, **217**
epidemiology/prevalence 213
etiology/pathophysiology 193, 213
management 199, *200*
transvaginal ultrasound diagnosis 192
placenta site trophoblastic tumor (PSTT) 444
placentation, definition 167
PMS *see* premenstrual syndrome (PMS)
polycystic ovary syndrome (PCOS) 387–396
definition 387
diagnosis **387,** 387–388
history/chief complaint 389–390, 391, **392**
laboratory evaluation 391
physical examination 390
TVUS 388, *388,* 391
epidemiology/prevalence 388
etiology/pathophysiology 388–389
metabolic abnormalities 388–389, **389,** *389,* 390, 391
reproductive hormones 388, *388*
hirsutism and hyperandrogenism 390, *390,* 394
menstrual dysfunction 389, 392
oligo-ovulation 390
treatment 391–394, **392**
dysfunctional uterine bleeding 394
hirsutism 394, *394*
infertility 392–393, **393, 395,** 407
obesity 392, 393
oligomenorrhea 392
polygenic traits/disorders 49
polyhydramnios (hydramnios), definition 167
polymenorrhea, definition 384
polymerase chain reaction (PCR)
herpes simplex virus diagnosis 222
prenatal testing 53
syphilis detection 228
polyploidy
definition 43
disorders 43–46
sex chromosomes and 46–47
see also specific conditions
polyzygotic birth, definition 167
POP-Q system 331
postabortal endometritis 288
postcoital test, infertility diagnosis/evaluation 405
posterior pelvic provocation test 252, *253*
post-maturity syndrome 266
postmenopause 421–431
adnexal mass evaluation 477–478, 479
definition 422
early *vs.* late 422

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

'hot flushes' 423, **424**
HRT *see* hormone replacement therapy (HRT)
increasing length of 421
see also menopause; perimenopause
postpartum ('baby') blues 247
postpartum depression 9, 242, 247
antidepressants and 247–248, **248**
screening 247
postpartum hemorrhage 211–218
definitions 211
diagnosis 212
history/chief complaint 214
physical examination 214–215
epidemiology/prevalence 212–213
etiology/pathophysiology 211, 213–214
management 215–217, 236–237, **239**
Sheehan syndrome and 381
see also third trimester bleeding; *specific causes*
postpartum mood disorders 247–249
nonpharmacological approaches 248
screening 247
see also specific conditions
postpartum period
definition 107
hemorrhage *see* postpartum hemorrhage
infection 211–218
puerperal endometritis *see* puerperal endometritis
see also specific infections/organisms
newborn care *see* neonatal care
psychiatric disorders and 242
see also specific conditions
postpartum psychosis 248
postpartum sexual dysfunction 492
postpartum thyroid disorders 257
postpartum tubal ligation *280,* 280–281
post-term pregnancy 265–270
definition 265
diagnosis 265, *265*
history/chief complaint 267
physical examination 267
etiology/pathophysiology 266
fetal consequences/risks 266, *266,* 268, 269
management/treatment
options 268–269
41-42 weeks 268
complications 269
delivery route 268
elective *vs.* expectant **269**
induction *268,* 268–269
maternal consequences 266
perinatal mortality and 268
prevalence 266
posttraumatic stress disorder (PTSD) 9
following sexual assault 497, **498**
posture, back pain and 260
Prader–Willi syndrome 50
preconception care 81–85
chronic disease and 84–85
see also specific diseases
definition 81
dietary supplements 85, **89**
history and 81–83
life-style factors 82, **82,** *82,* **83**
maternal age 81–82
importance 81
serological evaluation 84
standard recommendations **85**
pre-eclampsia–eclampsia syndrome 149–157
chronic hypertension and 150, 203, 205
diagnostic issues 204
complications/risk 149
definitions 149–150, 203
diagnosis 149–150
criteria **149**
differential diagnosis *150,* 150–151
HELLP syndrome 150, **150,** 152
history 152
laboratory evaluations 152, **153**
physical examination 152
proteinuria requirement 149, **149,** 152
eclamptic convulsions 149, 150, 155
epidemiology/prevalence 151
etiology/pathophysiology *151,* 151–152, 205
gestational hypertension and 204
stages 150
treatment **156,** 206–208, 236
antepartum steroids 153
antihypertensives 155–156, **156,** 207–208
conservative 153, **157**
eclampsia 155
fetal assessment 153, 155
fluid balance 154
hospitalization 153, **154**
labor induction 153, 155
maternal assessment 153, 154
pre-eclampsia 153–154
severe pre-eclampsia 154–155
thromboprophylaxis 155
pregnancy
antepartum care *see* antepartum care
dietary supplements 85
domestic violence and 495, 496
ectopic *see* ectopic pregnancy
following breast cancer therapy 357
hypertension and *see* hypertension, in pregnancy
infectious diseases *see* infections/infectious disease
lactogenic hormones 342
life-style factors and risks 82, **82,** *82,* **83**
maternal age *see* maternal age
medical complications 251–264
chief complaints/examination 257–259
definitions 251
diagnosis 252–254
epidemiology/prevalence 254
etiologies/pathogenesis 255–257
laboratory evaluations 259–260
treatment options 260–262
see also specific conditions
multifetal *see* multifetal pregnancy
obesity risks 87
obstetric history 17, **17**
ovarian cancer and 480–481
physiologic changes *see* maternal–fetal physiology
post-term *see* post-term pregnancy
preconception care *see* preconception care
psychiatric illness and *see* psychiatric disorders
screening during *see* prenatal testing
spontaneous loss (miscarriage) *see* spontaneous abortion
termination (induced) *see* therapeutic abortion
third trimester bleeding *see* third trimester bleeding
unplanned 81
epidemiology 275, 286
prevention *see* family planning
psychotic disorders and 246
weight gain 87
see also fetus; labor/delivery
pregnancy-associated plasma protein A (PAPP-A)
definition 65
prenatal testing 66
pregnancy-induced hypertension *see* pre-eclampsia–eclampsia syndrome
pregnancy wheel *265*
Premarin (conjugated equine estrogen) **430**
premature babies *see* preterm/premature babies
premature ovarian failure (POF) 381, 407, 423, 426
breast cancer and 351
see also menopause
premature rupture of membranes (PROM) 136, 137, 182, 183, 191–202
cervical length and 192, *192*
definition 191
diagnosis 191–192, *192*
history/chief complaint 195
laboratory evaluations 191, *196,* 196–197
physical examination 196
epidemiology/prevalence 192
etiology/pathophysiology 192–193
laboratory investigation 186, 191
management 193, 197–199
antibiotics 198, **200–201**
biophysical profiles 197–198
conservative 197, 198
fetal assessment and 198
labor induction 198
near term 198–199
steroids 198
WHO flowchart 197, *197*

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

multifetal pregnancy and 175
preterm delivery risk 197
premenopause 421
adnexal mass evaluation 477, **478**
physiology 423
premenstrual dysphoric disorder (PMDD)
definition 415
diagnosis 415–416
premenstrual syndrome (PMS) 415–420
definitions 415
diagnosis **415,** 415–416
history/chief complaints 416
symptom charts 416, **417**
epidemiology/prevalence 416
etiology/pathophysiology 416, 418
treatment 417–419
dietary interventions 418
drug treatments 418
ineffective/unproven 418–419
life-style changes 417–418
premutation, fragile X syndrome 50
prenatal care *see* antepartum care
prenatal history, hemolytic disease 161, **162**
prenatal testing 50–52, 65–70, 86, **88**
best evidence **54, 69**
biochemical markers 66, **69**
congenital syphilis 228
definitions 65
diagnostic tests 51, 68–69
first trimester 50–51, 66, 67, *67*
first *vs.* second trimester 67, *67*
integrated *see* integrated prenatal screening (IPS)
invasive tests 51, 68–69
laboratory techniques used 52–53, 68
multifetal pregnancy 174
noninvasive tests 51–52
nuchal translucency 51, 66, *66*
second trimester 66, 67, *67*
strategies 50–51, 65–68
timing/ethical issues 67
see also specific techniques
presacral neurectomy
chronic pelvic pain management 328
endometriosis management 321
prescription drugs *see* drug(s)
preterm labor/birth 135–145, 179–180
definitions 135, 179
diagnosis 136, 179–180
algorithm for **142**
cervical length and 141, 142, 145, 185
history/chief complaints 140, 183
laboratory tests (fetal fibronectin) 141–142, 179, **180,** 186, **189**
physical examination 141, 184–185
symptoms/signs 140, 183
ultrasonography 142, 185
epidemiology/prevalence 136, *136,* *137,* 181
etiology/pathophysiology 136–140, **138,** 182
cervical insufficiency 139
drug/alcohol abuse and 235
endocrine system and 139–140, **148,** 236
immunological/allograft rejection 139
infection/inflammation 137–138, **138,** 186, 236
multiple gestations and 136, 139
obstetric practices and 136, 182
PROM *see* premature rupture of membranes (PROM)
risk factors 137, *137,* **141, 180**
smoking and 235
socioeconomic status and 136, *137*
uterine ischemia 138
uterine overdistension 138–139
management 142–145, 184, 186–188
antibiotics 142–143, 188, 198, **200–201**
asymptomatic, high risk women 145
emerging treatments 188
hospitalization 142, 174
main goals 143
multifetal pregnancy and 174–175
PROM *see* premature rupture of membranes (PROM)
steroids *see* steroid-induced lung maturation
tocolytics *see* tocolytic therapy
neonatal complications 137
preventative measures 235–236
triage assessment 183, *184*
see also preterm/premature babies
preterm/premature babies
ethical dilemmas and 522
morbidity and 136–137, 182
mortality and 136, *136,* 233, 235
respiratory problems 107–108
antenatal steroids and prevention *see* steroid-induced lung maturation
thermoregulation 108, 112, *112*
see also preterm labor/birth
preventative medicine, medical economics and 503, **503**
primary ovarian failure *see* premature ovarian failure (POF)
privileges, legal issues 528
professional liability, medical economics and reform 504
progesterone
cholestasis and 255
corpus luteum 36
ectopic pregnancy and 121
ovulation role 35–36, *36,* 404
PMS/PMDD and 418
preterm labor/birth and 140
progestin-only pill 278, **278**
endometriosis-related pelvic pain and 319, **319**
menopausal hot flushes and 427
progestin withdrawal test 379–380
prolactinomas, secondary amenorrhea 380–381
prolactin-secreting pituitary tumors, secondary amenorrhea 380–381
prolapse (pelvic organ) 331–332, *332*
prostaglandins
dysmenorrhea 398
labor induction 268
ovulation role 35
proteinuria, pre-eclampsia–eclampsia syndrome, diagnostic requirement 149, **149,** 152
protozoan infections
pregnancy and 229–231
vaginitis and 300–301
see also specific infections/organisms
protraction disorder, definition 146
psychiatric disorders 8–9
breast-feeding and medications 247–248, **248**
following sexual assault 497, **498**
genetics 242
menopause and 426
postpartum 248
mood disorders *see* postpartum mood disorders
pregnancy and 9, 241–250
addressing psychiatric issues during 243–246
family planning and 241
medications and 244–245, **245,** 247–248
postpartum complications 242
risk factors for fetus 242, 244, **244**
risk factors for mother 242
see also postpartum mood disorders
see also specific disorders
psychosocial aspects of infertility 411
psychosocial support
following sexual assault 497
postpartum mood disorders 248
psychotic disorders, pregnancy and 246
PTEN mutations, endometrial cancer and 436, 472
pubarche, definition 31
puberty 4
definition 31
developmental milestones 4, *4*
menses initiation *see* menarche
weight/nutritional effects 5
puerperal endometritis
definition 212
delivery and treatment 215
diagnosis 212
epidemiology/prevalence 213
etiology/pathophysiology 213
pulmonary hypertension, antidepressant drugs and 245
pulse oximetry, fetal 97

Q

quad test 66

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

R

race *see* ethnicity/race
RADAR, domestic violence assessment 496
radial scarring, breast 346
radiotherapy
  breast cancer treatment 356
  cervical cancer therapy 458
  endometrial cancer 474
raloxifene
  bone density effects 428
  breast cancer prevention 352–353, **358**
rape *see* sexual assault
recessive traits/disorders 49
reciprocal translocations 47–48
rectocele (posterior prolapse) 331, *332*
rectovaginal examination 19, *20*
recurrent abortion 131
  definition 127
  incidence 128
renal function, maternal changes during pregnancy 76
reproductive hormones
  androgens *see* androgen(s)
  breast cancer risk 351–352, **357–358**
  estrogens *see* estrogen(s)
  polycystic ovary syndrome and *388,* 388–389
  see also specific hormones
reproductive risk factors, breast cancer 351
reproductive system
  anatomy 28–30
  definitions 25
  development/embryology *see* genital embryogenesis
  hormones *see* reproductive hormones
  see also specific structures/components
respiratory acidosis, definition 91
respiratory distress syndrome (RDS) 108, *108*
respiratory system
  fetal 107
  maternal changes during pregnancy 76, *76,* 255
  neonatal transition period 107–108
  see also steroid-induced lung maturation
retinoblastoma protein (Rb), HPV effects 436, 455
retrograde menstruation, endometriosis and 315, 316
rhabdomyoma 16
rhesus isoimmunization 159–166
  definition 159
  diagnosis 159
    Doppler ultrasonography *160,* **164–165**
    history/chief complaint 161–162, **162**
    invasive testing 162, *163,* 163–164
    laboratory evaluation 162–164
    physical examination 162
  epidemiology/prevalence 160, **160, 161**
  etiology/pathophysiology 160
    risk factors **162**
  fetal hemolysis 159, *159*
  IgM *vs.* IgG immunoglobulins 162–163
  'irregular antibodies' 160, **160**
  prophylaxis/antepartum care 86–87
    RhoGAM antibody therapy 159, 160
  therapeutic abortion and 286
  treatment 164
    fetal blood transfusion 163, *163,* 164
    neonatal management 164
rhythm method 276
ring chromosomes *48,* 48–49
ritodrine, as tocolytic agent 187, 235
Robertsonian translocation(s) 43, 48, *48*
robotic surgery, myomectomy 371–372, 466

S

sacrocolpopexy 332, *332*
saline infusion sonohysterography 375
salpingectomy, ectopic pregnancy management 122
salpingitis, *Chlamydia trachomatis* 306
salpingo-oophorectomy, risk reducing bilateral 353, 481
salpingostomy, ectopic pregnancy management 122
salpingotomy, ectopic pregnancy management 122
sarcomas, uterine 467
Sarcoptes scabiei 449
scabies, vulval lesions 449
Schiller test 21
schizophrenia, pregnancy and 246
second trimester screening 66
  first trimester *vs.* 67, *67*
seizures *see* convulsions
selective estrogen receptor modulators (SERMs), bone density effects 428
selective progesterone receptor modulators (SPRMs), uterine leiomyomas and 463, **468**
selective serotonin reuptake inhibitors (SSRIs)
  menopausal mood disorders 426
  PMS/PMDD management 418, **419**
  pregnancy and 244–245
  PTSD following sexual assault **498**
semen, infertility tests 404–405, **405**
sentinel bleeding 214
sentinel lymph node biopsy *355,* 355–356
septic abortion 127, 129
serological evaluation(s)
  antepartum care 86
  herpes simplex virus diagnosis 222
  HIV infection 224
  preconception care 84
  toxoplasmosis 230
serotonin, PMS and PMDD 416, 418
Sertoli–Leydig cell tumor 483
  virilization and 394
sex chromosome(s)
  definition 42
  genetic disorders
    Mendelian disorders 49
    numerical abnormalities 44, 45–47, *46*
    see also specific disorders
sex cord–stromal tumors 482–483
  see also specific types
sex differences
  health issues and 3
    mental health 8, 9, 243
  puberty and 4
sex hormone binding globulin (SHBG), polycystic ovary syndrome and 391
sex-specific behaviors 487
sex therapy, female sexual dysfunction therapy 491
sexual arousal 488
  disorders 490
sexual assault 496–498
  comprehensive care 497
  definition 496
  epidemiology/prevalence 496
  history taking/examination 497
  treatment 497
Sexual Assault Nurse Evaluation (SANE) program 497
sexual aversion disorder (SAD) 490
sexual dysfunction
  common problems in women 489–490
  general population 488, **488**
  history taking 488–489, **489**
  menopause and 425–426
  pain and 490
  postpartum 492
  treatment 491–492
  see also specific disorders
sexual history 17, 305, 488–489
  medical history and 489
  multifaceted approach **489**
  open-ended questions 488
  physical exam and **489**
  sexual function questionnaire 489
  see also sexually transmitted diseases (STDs)
sexual identity 487
sexuality 487–494
  adolescents 492
  chronic illness and 492
  dimensions *487*
  older adults 492–493
  sexual identity 487
  sexual responses 487–488
  see also sexual dysfunction; *specific dimensions*
sexually transmitted diseases (STDs) 305–310
  adolescents 492
  bacterial 305–307, **308,** 308–309
  ethical issues 524

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

maternal mortality and 238
non-ulcerative lesions 305–306
risk factors 305
screening 305
Chlamydia 306
HIV 224, 520–521
sexual assault and 497
syphilis 228
ulcerative lesions 306–309, **308**
viral 307, **308,** 309
see also pelvic inflammatory disease (PID); *specific infections/organisms*
Sheehan syndrome, secondary amenorrhea 381
shoulder dystocia 266, *266,* 269
sinusoidal patterns, fetal heart rate 95–96, *96*
skin tag, vulval 448
smoking
fertility and 409
fetal growth restriction and 182–183
preconception care and pregnancy 82
preterm birth/perinatal mortality and 235
primary ovarian failure 423
social factors/issues
contraception and 275
health care provision and 501–506
infertility 411
preterm birth/labor and 136, *137*
see also medical economics
somatarche 4
Southern blotting, prenatal testing 53, *53*
speculoscopsy, cervical screening and 456
speculum examination 18–19, *19*
sperm
donation 406
fertilization of ovum 37
spermicides 277
spinal manipulation, dysmenorrhea and 401
spirometry, asthma diagnosis 252, *252*
spironolactone, hirsutism management 394, *394*
sponge, contraceptive 277
spontaneous abortion 127–134
definitions 127
diagnosis 129–130
ectopic pregnancy *vs.* 121, *122*
etiology/pathophysiology 128–129
endocrine disorders 129
fetal defects 129
genetic 128, *128*
see also chromosome abnormalities
infection and 129
placenta and 129
procedure-related 129
recurrent abortion 131
structural problems 128, *129,* 131
thrombosis 128, 131
toxins/exposure-related 129
see also specific etiologies/risk factors
incidence 128
recurrent abortion 127, 128, 131
therapeutic abortion association 289
treatment
expectant *vs.* medical **132**
first *vs.* second trimester 130
outcomes **132**
post-treatment evaluation/counseling 131–132
squamous cell carcinoma, Bartholin gland 447–448
Stages of Reproductive Aging Workshop (STRAW) staging system 421–422, **422,** 425
standards of care 528
staphylococcal infections, vulval abscess 449
stem cells, cancer 438
stepwise sequential testing 68
sterilization
ethical dilemmas 523–524
female (tubal ligation) *280,* 280–281, *281,* 365
male (vasectomy) 281
steroid-induced lung maturation 142, 143, 174, 186, 188, 235
pre-eclampsia management 153
PROM management and 198
'strawberry cervix' 300, *300*
stress incontinence 333
diagnosis 333–334, *334*
management 334–335, *335,* **337**
stress, infertility and 411
suction curettage 286
suicide ideation 8–9
supracervical hysterectomy (SCH) 367, **375**
surgery, gynecological *see* gynecological surgery
surgical menopause 427
symphysiotomy, obstructed births 237–238
syngamy 37
syphilis 306–307
clinical features 227–228, *306*
congenital syphilis 228, **228,** 307
latent disease 306
late syphilis 227
late/tertiary syphilis 227–228, 306–307
primary syphilis 227, *227,* 306
secondary syphilis 227, **227,** 306
diagnosis **228,** 228–229, **229,** 307
following sexual assault 497
infection staging 226
pregnancy and 226–229
fetal infection routes 227
impact of disease on 227
management 229, *229*
preconception care and evaluation 84
prenatal testing 228
transmission 226, 306
treatment 307
pregnancy and 229, *229*
syphilitic chancre 227, *227,* 306

T

tachycardia, fetal 92
tachypnea, definition 107
tachysystole 100
tamoxifen, breast cancer prevention 352–353, **358**
TCu380A (Paragard) IUD 279
teratogens, prescription drugs 82, **83,** 244
teratomas 481
terbutaline, as tocolytic agent 187
terminal illness, medical economics and 503
testosterone
sexual dysfunction and 425, **493**
Turner syndrome 384
thecomas 482
thelarche, definition 31
therapeutic abortion 285–292
complications 287, 288–289
confirmation of success 287
counseling 286
definition 285
epidemiology 285–286
ethical issues 285, 522
failure 289
historical aspects 285
history/examinations 286
legal issues 285
long-term outcomes 289
methods/techniques
best evidence (clinical wisdom) **289–290**
first trimester 286–287, **287**
labor induction 288
medical abortion 286–287, **287,** *287,* **290**
risks 286, 287
second trimester 287–288
surgical methods 286, 287, **287,** *287*
timing of *288*
unsafe (illegal) 285–286
see also specific procedures
thermal neutral zone 109, *109*
thermoregulation, neonatal transition 108–110, *109, 110*
neonatal care and 111–112, *112*
thermoregulatory behaviors, neonatal period 110
third trimester bleeding 191–202
definitions 191
diagnosis 192
history/chief complaint 195
laboratory evaluation 197
physical examination 196
epidemiology/prevalence 192
etiology/pathophysiology 193–194
minor *vs.* serious causes 192
management 199, 215
delivery 215–216
outpatient *vs.* inpatient 215
mortality associated 191
postpartum hemorrhage and 214, 215
see also postpartum hemorrhage
see also specific causes

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

threatened abortion, definition 127
3-IQ questionnaire 333, *334*
three delays model 528, *528*
thrombocytopenia, definition 219
thrombophilia
  definition 16
  pre-eclampsia/eclampsia and 155
  spontaneous abortion and 128, 131
thyroid disorders 6
  definition 251
  hyperthyroidism *see* hyperthyroidism
  hypothyroidism *see* hypothyroidism
  postpartum 257
  pregnancy and
    chief complaints/examination 258–259
    diagnosis 254
    epidemiology/prevalence 254
    etiology/pathogenesis and 257
    laboratory evaluation 260
    management 262
    preconception care and 84
    spontaneous abortion and 129
  see also specific diseases
thyroid gland
  disorders *see* thyroid disorders
  fetal 78
'thyroid storm' 259
tobacco, preconception care and pregnancy 82
tocolytic therapy 143, 186–188, 235
  agents used 143, 186, **186**
    emerging treatments 188
    second-line drugs 188
  mechanism of action **143**
  multifetal pregnancy and 175
  side effects/contraindications **144, 186,** 187, **187**
  see also specific agents
total abdominal hysterectomy (TAH) 367
toxins, spontaneous abortion and 129
Toxoplasma gondii 229
  life cycle 229
  see also toxoplasmosis
toxoplasmosis 229–231
  congenital *see* congenital toxoplasmosis
  diagnosis 230
  preconception care and evaluation 84, 230
  primary prevention 230, **230**
  screening controversy 230
  transmission 230
transcutaneous electrical nerve stimulation (TENS)
  back pain and *260,* 260–261
  dysmenorrhea treatment 401
transgendered individuals 487
transient hypertension (in pregnancy) 205, 208
transition period, definition 107
trans-sexuals 487
transvaginal ultrasonography (TVUS)
  chorionicity assessment 171
  placenta previa diagnosis 192
  polycystic ovary syndrome diagnosis 388, *388,* 391
  postpartum hemorrhage 215
  spontaneous abortion diagnosis 129
trastuzumab, breast cancer treatment 356
Treponema pallidum 226, *307*
  see also syphilis
Trichomonas vaginalis 300, *300*
trichomoniasis 300–301
  causative organism 300, *300*
  clinical features/diagnosis *300,* 300–301
  epidemiology 300
  sexual activity and 300
  treatment 301
trinucleotide repeat disorders 49–50
triple test 66
triplets, labor/delivery 178
triple X syndrome (47,XXX) 46
trisomies 44–46
  definition 65
  isochromosomes and 48
  spontaneous abortion and 128, *128*
  see also specific conditions
trisomy 13 (Patau syndrome) 44–45, *45*
trisomy 18 (Edwards syndrome) 45, *45*
trisomy 21 (Down syndrome) 44
  isochromosomes and 48
  karyotype *68*
  maternal age and 44, *44,* 65, 68
  phenotypic features 44, *44*
  prenatal screening 50–51, 65
    CVS 68
    serum markers 66, **69**
    see also prenatal testing; *specific methods*
  spontaneous abortion and 128, *128*
trochanteric belts 261
trophoblast 38
tubal ligation *280,* 280–281, *281,* 365
tubal pregnancy *see* ectopic pregnancy
tubo-ovarian abscess 313
tumor(s)
  immunology 438
  pituitary, secondary amenorrhea 380–381
  virilization and 394, 395
  see also cancer; *specific types/locations*
tumor suppressors, HPV effects 436, 455
Turner syndrome 44, 46, *47*
  breast development 383–384
  growth hormone therapy 383
  isochromosomes and 48
  primary amenorrhea 383–384
  primary ovarian failure 423
'twin-peak sign' 172
twins
  complications *170,* 170–171
  epidemiology 168, **169**
  etiological factors 169
  fetal position and delivery 176–177, *177*
  see also multifetal pregnancy
twin-to-twin transfusion syndrome *170,* 170–171
'two-cell, two-gonadotropin theory' 33–34, *34*

U

ulcers, vulval lesions 449
ultrasonography 22–23
  adnexal mass evaluation 477
    ovarian cancer 479
  breast mass evaluation 345
  cholecystitis diagnosis 253, *253*
  fibroid diagnosis 371
  hydatidiform mole diagnosis 441–442
  infertility diagnosis/evaluation 405
  MRI-guided 467
  obstetric
    due date and 265
    ectopic pregnancy diagnosis 119, 121, *121*
    fetal growth restriction assessment 185–186, *186*
    intrapartum fetal surveillance 96
    multifetal pregnancy and 168, *168,* 171–173, *173,* 174
    nuchal translucency 51, 65, 66, *66*
    postpartum hemorrhage 214–215, **217**
    preterm labor/birth and 142, 185, 192, *192*
    rhesus isoimmunization and 159, *160,* **164–165**
    spontaneous abortion diagnosis 129
    standard antepartum care 86
    vasa previa and 196
  uterine leiomyomas 462
  see also specific modalities
ultrasound biometry, fetal growth restriction 185
unconjugated estriol
  definition 65
  prenatal testing 66
United Nations Population Fund, three delays model 528, *528*
urge incontinence 333
  diagnosis 333–334, *334*
  management 335–336
urinary incontinence 333–336
  diagnosis 333–334, *334*
  incidence 333
  management *12*
    bulking injections **337**
    medical 335–336
    nonsurgical 334–335, 335–336
    stress incontinence 334–335, *335,* **337**
    surgical 335, *335*
  menopause and 12, 426
  pathogenesis 333
  subtypes/classification 333
  see also specific types

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

urinary tract
infections 336
pelvic pain and **325,** 326
urodynamics 333–334
uterine artery
embolization, uterine leiomyoma management 7, 466, **468**
occlusion, uterine leiomyoma management 466–467
uterine atony
definition 212
diagnosis 212
epidemiology/prevalence 213
etiology/pathophysiology 214
management 216, **216,** *217*
therapeutic abortion and 289
uterine bleeding, dysfunctional 384–385
endometrial cancer and 472
polycystic ovary syndrome and 394
uterine leiomyomas and 462
uterine sarcomas and 474
see also specific types/causes
uterine contractions
dysmenorrhea 398
parameters 99–100
pharmacological inhibition 401
uterine fibroid embolization (UFE) 7, 466
uterine ischemia, preterm labor/birth and 138
uterine leiomyomas 7–8, 461–470
definition 16, 370
diagnosis 7, 371, 462
dysmenorrhea and 399
epidemiology/incidence 7, 371, 461
etiology/pathophysiology 461, **461,** *461*
infertility and 408
locations 370, *370,* 461, *461*
management 7–8, 371, 462–467
embolization/occlusion 466–467, **468**
hysterectomy *vs.* other methods 366, **468**
medical treatment 462–463, **468**
myomectomy *see* myomectomy
surgical treatment 463–467, **468**
treatment options 462, **463**
see also specific methods
necrosis 462, 466
sarcomas *vs.* 467
symptoms/signs 7, 462
uterine leiomyosarcomas 474–475
uterine nerve ablation, dysmenorrhea and 401
uterine overdistension, preterm labor/birth and 138–139
uterine perforation
IUDs and 280
therapeutic abortion and 289
uterine rupture
definition 191
diagnosis
history/chief complaint 195
physical examination 196
epidemiology/prevalence 192
etiology/pathophysiology 194, **194**
management 199
uterine sarcomas 467, 474–475
uterine suspensory ligaments 28, *29*
uterogenic agents 236–237
postpartum hemorrhage management **239**
see also specific drugs
uterus
anatomy 28, *29,* 461, *461*
bimanual examination 19, *19*
'boggy,' adenomyosis and 321
cervix *see* cervix
hypocontractile 146
infertility and 408
lesions
fibroids *see* uterine leiomyomas
sarcomas 467, 474–475
multifetal pregnancies and 170
prolapse 331, 332, *332*
secondary amenorrhea and 382
structural abnormalities
developmental 25, **25,** *27*
infertility and 408
spontaneous abortion and 128, *129*
see also entries beginning utero-/uterine; specific conditions/abnormalities

V

vaccination
antepartum care 86–87
human papilloma virus (HPV) 4–5, 455
medical economics, developed countries 503, **503**
vacuum aspiration 286
vacuum extraction 105
vagina
bimanual examination 19, *19*
biopsy 21
common developmental abnormalities **25**
inflammation *see* vaginitis
lesions 447–452
intra-epithelial neoplasia 450–451
malignant *see* vaginal cancer
vaginal wall cysts 448
menopause and 425, 426, 428
normal physiology/flora 293–294
rectovaginal examination 19, *20*
speculum examination 18
see also entries beginning vaginal
vaginal bleeding, molar pregnancy 442
vaginal cancer 451
premalignant lesions 450–451
surgical staging and survival 451, **451**
vaginal delivery
HIV infection and 224
multiple births 176–177
placenta previa and 199
vaginal discharge
bacterial vaginosis 298, *298*
fallopian tube cancer 483
normal 293–294
trichomoniasis 300
vulvovaginal candidiasis 296, *296*
vaginal dryness, therapy 491
vaginal fluid, PROM diagnosis 196
vaginal intra-epithelial neoplasia (VAIN) 450–451
vaginal introitus, definition 107
vaginal slings 335, *335*
vaginal surgery 363–364
hysterectomy 367–368, *369*
vaginal symptoms, menopause and 425
vaginal uterine artery occlusion, uterine leiomyoma management 466–467
vaginal wall cysts 448
vaginismus 490
vaginitis 293–301
definition 293
diagnosis 294–296
clinical features 294, **294**
history 295
office analysis **295,** 295–296
physical examination 295
epidemiology/prevalence 293
etiology/pathophysiology 293–294
infectious 293, **293,** 294, 296–301
noninfectious 293, **293,** 301
see also specific organisms/conditions
types 296–301
valacyclovir, HSV transmission reduction in discordant couples **309**
vasa previa
definition 191, 212
diagnosis 212
history/chief complaint 195
physical examination 196
epidemiology/prevalence 213
etiology/pathophysiology 193–194, *194,* 214
management 199, 216
vascular endothelial growth factor (VEGF), angiogenesis and cancer 437–438
vasectomy 281
vasospasm, pre-eclampsia–eclampsia syndrome 151–152, 205
vertical transmission
definition 219
HIV 224
toxoplasmosis 230
vestibulodynia 490
violence
domestic *495,* 495–496
sexual assault *see* sexual assault
viral infections
cervical cancer and *see* human papilloma virus (HPV)
pregnancy and 219–225
prophylactic treatment following sexual assault 497

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers

sexually-transmitted diseases 307, **308,** 309
see also specific organisms/infections
viral titer, definition 219
viremia, definition 219
virilization 394–395
Sertoli–Leydig cell tumors 483
vitamin D supplements, menopause 428
vitamin K prophylaxis 112
vomiting, pregnancy 256
vulva
biopsy 21, 450
inflammation *see* vulvitis
lesions 447–452
intra-epithelial neoplasia 449–450
malignant *see* vulvar cancer
palpable 447–448
pigmented 448
pustules/vesicles 449
ulcers/fissures 449
see also specific types/causes
pain 302
see also entries beginning vulvo-/vulvar
vulvar cancer 450
etiologies 450, **452**
premalignant lesions 449–450
staging 450, **450**
surgical management 450
vulvar dermatoses 302–303
cancer link 450
vulvar intra-epithelial neoplasia (VIN) 449–450
vulvitis 301–303
clinical features/diagnosis 302–303
definition 301
etiology/pathophysiology 301–302
treatment options 302, 303
see also vaginitis
vulvodynia 490
vulvovaginal candidiasis 296–298
classification 297, **297**
clinical features/diagnosis 296–297
laboratory tests *296,* 296–297
vaginal discharge 296, *296*
overgrowth pathophysiology 296
recurrent 297, 298, **303**
risk factors 296
treatment 297–298
complicated disease 297–298
recurrent disease 298, **303**
symptomatic relief 297
uncomplicated disease 297, **297**

W

weight control
antepartum care and 87
multifetal pregnancy 173
birth to adolescence 5
hormonal contraception and 278
see also nutrition; obesity
'whiff' test 295–296
withdrawal, contraception and 276
Women's Health Initiative study (WHI)
HRT and breast cancer 11
HRT benefits 429, **430**
World Health Organization (WHO)
contraception guidelines 5, **6**
post-term pregnancy definition 265
PROM management recommendations 197, *197*
Surgical Checklist 504, **504–505**

X

X-chromosome disorders
fragile X syndrome 50, 426
numerical abnormalities 45–47, *46, 47*
premature ovarian failure 381, 423
primary amenorrhea 382
recessive disorders 49
see also specific conditions
X-linked inheritance 49

Z

Zestra, sexual dysfunction management 492
zygote 37, 38

aus: Reece u.a., Obstetrics and Gynecology (ISBN 9783131439512) © 2010 Thieme Medical Publishers